Report of the fifteenth session of the Joint Action Forum

JOINT ACTION FORUM Office of the Chairman JAF-FAC: SIXTEENTH SESSION Abuja, 7 - 9 December, 2010 FORUM D'ACTION COMMUNE Bureau du Pr6sident D I African Programme for Onchocerciasis Control Programme africain de lutte contre l'onchocercose REPORT OF THE FIFTEENTH SESSION OF THE JOINT ACTION FORUM JAF I6.4 ORIGINAL: ENGLISH October 2010 I il7 JAFI6.4 Page i Table of Contents Acronyms... Opening of meeting Election of officers Special Presentation : The development of partnerships ...,.......... Address by a community leader from Chad Adoption of agenda.... Reflections of the Committee of Sponsoring Agencies (CSA) WHO progress repoft.... Statements by Ministers of Health.. Treatment coverage: presentation by representatives ofcountries.............. Government Contributions ............... Reporl of the Technical Consultative Comminee (TCC) Sub-regional Ministerial meeting on cross-border collaboration................ Status of onchocerciasis transmission in Africa Elirnination of onchocerciasis transmission in Africa, where feasible ........ Co-implementation in Tanzania Statements by Partners. Training of CDDs Outcome of the closed door sessions.................. Statement by Ministers of Health Statement by NGDO Group Statement by Donors Health Impact Assessment of APOC operations Report of the NGDO Coordination Group for Onchocerciasis Control ......, Update from the Multi-Disease Surveillance Centre (MDSC) Current research within APOC and TDR collaboration ................. Audit Report Addendum to Plan of Action and Budget 2008 - 2015........... Plan of Action and Budget for 2009 Financing of the African Programme for Onchocerciasis Control(APOC). Donor Pledges....... Other matters ............... Special tribute to champions of onchocerciasis control Date and place of JAF16................ Review of Final Communiqud................. Closure of the Fifteenth JAF Session Annexes Annex l: List of participants ................ Annex 2: Provisional Agenda... .ll .l .2 .J .J .3 .J .4 .4 .7 .8 .8 .9 .9 10 10 J 2 2 t4 t4 t4 5 ll l8 l8 l8 15 l5 .... l3 13 ....... 16 ....... t7 ..........18 ..... l8 ..... l9 t9 ...... JJ JAFI6.4 Page ii Acronyms AfDB APOC CAR CDDs CDI CDTI CSA DALYs DRC ECCAS ECOWAS FLHF JAF LF MDA MDGs MDP MoH MDSC NGDO NTDs OCP PAB SAEs SIZ SSI STH TCC TDR USAID WAHO wHo African Development Bank Africa Programme for Onchocerciasis Control Central African Republic Community Directed Distributors Community Directed Intervention Community Directed Treatment with Ivermectin Committee of Sponsoring Agencies Disability Adjusted Life Years Democratic Republic of the Congo Economic Community of Central African States Economic Community of West African States Front Line Health Facility Joint Action Forum Lymphatic Filariasis Mass Drug Administration Millennium Development Goals Mectizan Donation Programme Ministry of Health Multi-Disease Surveillance Centre Non-Governmental Development Organisation Neglected Tropical Diseases Onchocerciasis Control Programme Plan of Action and Budget Serious Adverse Events Special Intervention Zones Sight Savers lnternational Soi l-Transmitted Helminths Technical Consultative Committee Special Programme for Research and Training in Tropical Diseases United States Agency for International Development West Africa Health Organization World Health Organization JAFI6.4 Page I Opening of meeting 1. The Fifteenth Session of the Joint Action Forum (JAF) of the African Programme for Onchocerciasis Control (APOC) was hosted by the African Development Bank (AfDB), from 8 - l0 December 2009 in Tunis, Tunisia. The meeting was attended by Honourable Ministers and Deputy Ministers, Permanent Secretaries and Directors of Public Health and Disease Control of 23 APOC and former OCP countries, 2l representatives of the donor community, WHO Geneva, WHO/AFRO, the West African Health Organization (WAHO), the Economic Community of Central African States (ECCAS), Non-Governmental Development Organizations (NGDOs), the Mectizan Donation Programme, Merck & Co. Inc., Pftzer Pharmaceuticals, Research [nstitutions, Directors and Coordinators of National Onchocerciasis Control Programmes and Representatives of the Statutory Bodies of APOC. A complete list of participants is attached as Annex 1. 2. JAF thanked the Government of Tunisia for the warm hospitality, and the AfDB for hosting JAF I5. 3. On behalf of Dr Donald Kaberuka, President AfDB - Dr llunga, head of the Health Sector AfDB, welcorned JAF participants to Tunis. He acknowledged APOC's position as a model of strong partnership which includes governments, donors and civil society. APOC has indeed shown a lot of success in Africa, caring for over 50 million people at risk of onchocerciasis. 4. Dr Ok Pannenborg, World Bank, introduced a tribute to Dr Robert McNamara, former President of the World Bank, who passed away in 2009. During his tenure at the Bank, Dr McNamara played a pivotal role in initiating the onchocerciasis control programme. A memorial tribute film was shown to JAF, in which the President of the World Bank reiterated its commitment to APOC until the closure of the programrne. 5. Dr Uche Amazigo, APOC Director, expressed her sincere gratitude to Dr Donald Kaberuka, President AfDB, for hosting, for the first time, the governing body of this truly unique partnership - engaged in the complex fight against river blindness in Africa. Forty one years ago, in 1968, the first ever meeting to discuss the search for scientific tools to control the untold human suffering and economic devastation of river blindness was hosted by WHO in Tunis. By fate, the l5th session of the governing body is being hosted by the AfDB in the same city where it all began. APOC is a regional programme with strong ownership by African countries, therefore the strong support given by the AfDB to APOC symbolises the great impoftance President Kaberuka attaches to the role of health in the economic development in Africa. 6. Remarkably, seven of the nine major donors have been with the campaign continuously over three decades. Dr Amazigo reiterated APOC's gratitude to the donors and to traditional NDGOs whose continued commitment and confidence in the programme has now brought us to a stage at which countries can show evidence that elimination of river blindness in Africa is being accomplished. APOC partners have put in place a community-driven strategy and a huge cumulative grassroots workforce of over half a million trained community selected drug distributors in l5 countries who are addressing the control of onchocerciasis and other diseases of poverly. A critical requirement is the continued commitment of the donor community, NGDOs and in particular the governments. 7. Two musical artists Amity Meria from Burkina Faso and Upendo Kilahiro from Tanzania gave tribute through songs to the CDDs for their hard work under difficult conditions in the communities. 8. Dr Stephen Mallinga, Minister of Health Uganda, and outgoing Chair of JAF 14, highlighted the Programmes key achievements in 2008 and 2009. Despite the prevailing conflict situation in some countries, APOC management and the National Onchocerciasis Task Forces successfully expanded the search for new and untreated onchocerciasis endemic villages through disease mapping and refinement in Burundi, Cameroon, CAR, Sudan and Ghana. In 2008, almost 57 million persons in 120,000 JAFI6.4 Page 2 communities were treated using CDI. Sixteen projects were evaluated of which twelve performed well. During 2008-2009,418,000 CDDs and 39,000 health workers were trained and re-trained by CDTI projects, representing in an increase of l8% for CDDs and 6%o for health workers compared to2007 figures. In addressing the issue of gender mainstreaming, l5 candidates, of whom 12 are female, were selected in 2009 to receive APOC-supported scholarships for Masters degree studies at public health institutions and Universities in Africa. 9. Other key activities and accomplishments in 2008-9 included: epidemiological evaluations in Nigeria, Chad, Uganda and Tanzania - with positive results showing good decline of the epidemiological parameters; APOC's support in organising ministerial meetings on cross-border issues related to onchocerciasis and other disease surveillance and control in West and Central Africa in line with a recommendation of JAFl4. 10. Dr Luis Gomes Sambo, Regional Director WHO/AFRO, highlighted in his statement the effectiveness of APOC's CDTI strategy, which has proved effective in promoting primary health care through the control of onchocerciasis. The burden of disease, including other NTDs, constitutes a major obstacle to human development in the African Region. Ministers of Health and WHO jointly agree that health system strengthening, based on a primary health care approach, is the right response to cope with current public health problems. This requires strengthening local capacities to deliver quality health care. and empowering communities to participate in decisions concerning their own health and development. The community-directed intervention strategy (CDI) pioneered by APOC has the potential to promote primary health care, having also facilitated the delivery of integrated packages of interventions by the communities, for the communities. Dr Sambo called upon Governments to increase their commitment in terms of funding, disease surveillance, cross-border collaboration, and in the creation of Centres of Excellence. This will strengthen the regional capacity for research to generate evidence for decision-making by governments in the areas of epidemiological surveillance, public health, and quality control of drugs and food. Dr Sambo informed JAF that, with respect to this, a project document was being finalised and would be discussed with the Economic Community of West African States (ECOWAS) Member-States and development partners with the aim of transforming the current Multi-Disease Surveillance Centre (MDSC) in Ouagadougou into a Centre of Excellence for Disease Control. 11. Dr Donald Kaberuka, President AfDB and host of JAF 15, officially opened the meeting. In his remarks he commended APOC's CDTI strategy which is based on the mobilisation of members of the communities concerned and the participation of local NGOs. These key elements are crucial to the sustainability and consolidation of activities. The AfDB has been supporting onchocerciasis control since the operation was launched in 1975. Recognising the crucial nature of this last phase of the APOC programme, AfDB approved in July 2008, funding to the tune of US $23 million to strengthen the project's achievements and to finalise the disengagement process and the devolvement of activities to countries. In addition, thanks to this funding, gender issues will be better addressed, particularly in terms of improved services for women, given that this is a core element for sustaining such activities. Moreover, Dr Kaberuka highlighted that AfDB's strategic approach to regional integration is in line with that of APOC - a programme which is a good model of an integrated regional approach, connecting various regional bodies in West, East and Central Africa. Lastly, Dr Kaberuka reiterated AfDB's commitment to continue supporting the programme according to their sigrred agreement. Election of officers 12. JAF elected the Government of the Republic of Cameroon, in the person of Mr Andrd Mama Fouda, Minister of Health, as Chair of JAF 15, and the Government of the Republic of Tanzania as Vice Chair, in the person of Professor David Mwakyusa, Minister of Health, Tanzania. The African Development Bank, as host of the meeting, was elected as Executive Chair for JAF 15. JAF thanked the outgoing Chair, Dr Stephen Mallinga, Minister of Health Uganda, for his leadership as Chair of JAF I4. JAF16.4 Page 3 13. In his acceptance speech, Mr Andrd Mama Fouda, thanked APOC for its financial and technical support to Cameroon. He thanked donors and partners for their support in the fight against onchocerciasis and called for additional support to eliminate the disease as a public health problem. 14. Professor David Mwakyusa, Vice-chair JAF, congratulated the new chair. He then requested that APOC management reports on the implementation of the decisions of the previous JAF. Special Presentation: The development of partnerships 15. Professor Allen Foster, President of CBM, gave a presentation on the history of onchocerciasis control which emphasized that the partnership between donors, NGDOs, APOC and countries is key to the success achieved to date. This partnership needs to be sustained and expanded to achieve the new objectives of co-implementation for NTDs and elimination of transmission of onchocerciasis. 16. JAF thanked Professor Foster for his visionary presentation Address by a community leader from Chad 17. Mr Pircolossou, a community leader and former onchocerciasis patient from Chad, addressed JAF and thanked partners, including Merck and other pharmaceutical companies for providing drug donations to the African people. He also thanked APOC for improving the health status of the African population. Good health is a basic human right and an important factor in the attainment of happiness, which is deserved by all Africans. Mr Pircolossou explained that within his communities people are convinced that treatment with ivennectin is the best way to ensure that people have access to health care services, and acknowledged the support of the Ministries of Health (MoH), APOC, donors and the NGOs. Mr Pircolossou concluded by calling upon other institutions to follow the leadership of the AfDB in acknowledging the suffering of Africans. Adoption of agenda 18. The provisional agenda appended as Annex 2 was adopted without any amendments. Reflections of the Committee of Sponsoring Agencies (CSA) 19. The reflections of the Committee of Sponsoring Agencies (CSA) were presented by Dr Chris Mwikisa, Chairman of the Committee. CSA recognised that the long-term commitment and sustained political will of National Governments and the steadfast support of donors and NGDOs to river blindness control continues to be recognised as one of the most significant major public health and development successes in Africa. Of the 20 APOC partners today, many have been with the programme for 2 or 3 decades. Since 1995, the equivalent of more than $1 billion has been invested, and the excellent use of funds by the programme has allowed for the development of high levels of partner confidence in APOC. APOC, a programme 'for Africans, by Africans', with a return on investment of 160/o-20%o, today remains one of the most successful and largest public health programmes in the world. 20. Dr Mwikisa informed JAF that 2009 had been a year of important growh and innovative developments for APOC. Over 56 million people from over 120,000 communities in Africa were treated with Ivermectin with an average coverage of 70%o. Furthermore, APOC made significant contributions towards strengthening national health systems and primary health care through iapacity building of community and front-line health facility staff and provision of equipment. Training or re- training of 420,327 CDDs and 39,727 health workers from all levels was aCcomplishea Uy COff projects. A curriculum on CDI was also launched for teaching the strategy in medical and nursing schools in l8 universities of I I countries in sub-Saharan Africa. Other CSA activities during 2009 JAFI6.4 Page 4 were the development of a supplementary addendum to the strategic plan of action 2008-2015 and the finalisation of donor agreements. 21. ln his concluding remarks, Dr Mwikisa stressed that APOC has a robust infrastructure that can be put to use in addressing the severe suffering caused by NTDs, and that many other partners have shown interest in moving in this direction in terms of financial support or implementation - while African governments have indicated the importance of addressing NTDs. It is therefore the view of CSA that as APOC maintains focus on its onchocerciasis mandate, bridges should be built to reach out to other partners to see how the agenda of NTDs can be moved forward in support of countries. CSA commended APOC management for the excellent work they continue to perform and the partners for their continued investment in APOC - it is through this collaboration that APOC's successes and achievements in the countries have been possible. Finally, acknowledgement was made of the ownership and leadership taken by governments to ensure that after APOC's exit, the achievements will be sustained. WHO progress report 22. APOC Management presented JAF with an overview of key activities carried out by the programme in 2009, such as CDTI; strengthening health systems; co-implementation of CDTI with other health interventions and elimination of onchocerciasis transmission. In collaboration with the MDSC, APOC countries and 6 ex-OCP countries undertook a number of capacity building activities, including the training of staff in mapping CDTI and entomology, during 2008-2009. [n the same reporting period, four ex-OCP countries also received both financial support and training in mapping, entomology, epidemiology, administration, finance and management of CDTI, as a means of building their capacity. As a result, major improvements were observed, especially in Cote d'lvoire. Additionally, l8 African Faculties of Medicine, Schools of Nursing and School of Public Health approved the inclusion of the CDI strategy in their curricula. APOC management informed JAF that the programme had provided funding in 2009 for Masters degree level training to 15 individuals, l2 of whom are female, thus addressing the gender mainstreaming aspect brought up the JAF during the 14th session. 23. Concerning co-implementation, since the endorsement of CDTI as a platform for co- implementation by the WHO Regional Committee during a meeting in 2007, APOC has doubled financial and technical input to countries for key CDTI activities. Subsequently, there was an increase in the number of people treated through CDTI, which reached 57.6 million in 2008. Among these, multiple interventions were provided to 37 million people for malaria management, Vitamin A supplementation and control of other NTDs. It was noted that major efforts were being made by countries, in collaboration with other partners, to diversiff and improve health services through co- implementation using the CDI strategy. Lastly, progress was made in the mapping of onchocerciasis and from 199'1-2009, more than 11,600 villages were surveyed in l9 countries and3,562 villages were surveyed using RAPLOA in 8 countries. 24. Following the presentation, JAF commended APOC management and countries for the progress made during the reporting period, with respect to increased treatment coverage; successful co-implementation of activities using the CDI strategy; and the shift from control to elimination of transmission of infection where feasible. JAF requested that APOC management reports on the implementation of decisions of the previous JAF during future JAF sessions. Statements by Ministers of Health 25. Statements were given to JAF by Ministers of Health of the following APOC and ex-OCP countries: JAFI6.4 Page 5 a) Burkina Faso: Onchocerciasis is no longer a public health problem and has been controlled in 85 sentinel villages situated in the river basins. However, in200718 some villages had prevalences above tolerable levels, thus it was deemed necessary to conduct research in these villages to assess the situation. During 2009, entomological surveillance was carried out in 10 sentinel villages and samples were sent for laboratory analysis. In terms of the financing of onchocerciasis activities, CFA 26 million was spent in 2009, 65 % of which was paid by the government budget. b) Burundi: Additional financial technical support is needed in this post-conflict country, in which over 1,400 million people (17 % of the population) are at risk of onchocerciasis, in five out of the seventeen provinces. Currently, the three CDTI projects in the country achieve a geographical coverage of 100 %o and therapeutic coverage of 60Yo, although there are efforts to increase therapeutic coverage to 90%o. Furthermore, there is a gradual increase in the health budget in order to improve health indicators linked to the MDGs. c) Cameroon: Blindness is a serious public health problem in Cameroon and onchocerciasis is endemic throughout the country. In 2009, the number of CDDs was increased to 25,000, and this resulted in an increase in treatment figures. The country has developed plans for NTD control for the period 2001-2011, and is in the process of drawing up its exit plan for onchocerciasis control. Following the recommendations of JAF 14, Cameroon organised a sub-regional cross-border Ministerial.meeting in October 2009. During the curent reporting period, several cases of SAEs were observed following treatment with doxycycline and APOC provided financial support for monitoring SAEs in the Littoral project area. Mapping is underway for NTD control to be implemented in 2010, and the country called upon development paftners to support the planned co-implementation of integrated health interventions. d) Central African Republic (CAR): Onchocerciasis is endemic to 10 out of the 16 prefectures of CAR, putting 2 million (almost 50%) of the country's population at risk. Itching and skin problems caused people to abandon agricultural land, resulting in serious socio-economic consequences for a country with a weak economy. The Government has renewed its commitment to onchocerciasis control and has been training CDDs and health workers as well as providing staff for effective implementation of the CDTI strategy. The country's sustainability and exit plans have just been finalised and will require financial support up to 2015. CAR has developed a strategic plan for integrated control of NTDs as well as a 3 year Plan of Action with support from WHO. e) Chad: CDTI implementation has been ongoing since 1998 and encouraging results have been achieved. More than 19,072 health workers and 13,000 CDDs have been trained and are now working in 3,000 villages, achieving geographical and therapeutic coverages of 100 and 800/o respectively. CDTI has been integrated into the primary care health system and CFA 50 million has been approved by the government for onchocerciasis control activities. These activities currently include: treatment impact assessments, development of a plan for integrated mapping of NTDs by 2010, development of a full system of surveillance and the organisation of a second sub-regional Ministerial cross-border meeting in Ndjamena in 2010. A plea was made to all partners for financial support for these activities. f) Cote d'Ivoire: Onchocerciasis is endemic throughout Cote d'Ivoire. Control activities increased in 2009 with more people being trained or retrained. Among these, 59 doctors, 331 health workers, and 7,038 CDDs were trained or retrained and ivermectin was distributed to 3,519 communities in 50 health districts. Epidemiological and entomological evaluations are currently in progress. Mobilisation of partners to support these activities and strengthen capacity is in progress. Cote d'Ivoire is conscious of its role in the programme for elimination of onchocerciasis and has contributed US $590,000, including equipment. A National programme for control of LF, STH and schistosomiasis will be implemented with CDTI and will require operational research and continued international support. g) Equatorial Guinea: Onchocerciasis control is progressing despite some challenges, and encouraging data has shown that elimination of the vector, Simulium yahense, has been achieved in Bioko. From 2005 to the present, no blackfly has been found on that island despite many surveys - the JAFI6.4 Page 6 vector is totally absent. This is a very important scientific milestone for donor countries andinstitutions fighting the scourge of river blindniss. CDTI will continue to be used to free carriers of theparasite in the population and entomological monitoring will also continue. The political commitment of the Government will ensure continued financing of onchocerciasis control in the country. h) Guinea: Twenty-four out of the country's thirty-three districts are affected by onchocerciasis, with more than 20,000 people at risk. Between 2000 and 2008, a cumulative total of i+,OOO CDDs treated 2 million people in 8,000 villages using CDTI. The country also held cross-border meetings with neighbouring countries in 2009. Lastly, the partners were requested to provide both financial and technical support in order to strengthen surveillance activities. i) Guinea Bissau: The AfDB was thanked for covering travel expenses for the delegate of Guinea Bissau to JAF 15. Efforts were being made to improve both geogriphical and therapeutic coverages, including the training of 63 trainers in 2009, who will in turn tiain tObO CDDs. A request was made to APOC to provide teaching materials in portuguese. j) Ghana: The devolved Onchocerciasis control programme in Ghana is aimed at sustaining the gains of OCP, preventing recrudescence, eliminating the disease in 'black Spot' areas and extending onchocerciasis control to the endemic communities in the forest belt of the country. A draft 5 yeai strategic plan on NTDs has been developed, covering onchocerciasis, LF, schistosomiasis, STH and Trachoma. In 2008, geographic and therapeutic coverages were 97.8% and 72.2o/o respectively and 718,985 people from 1,283 communities received bi-annual treatments with ivermectin. Epidemiological surveys conducted in 2001 in these communities showed significant decreases in the prevalence of infection. k). Liberia: The country is committed to the implementation of the poverty reduction strategy, including the global effort to fight onchocerciasis. Treatment and geographical covera ges were 70o/o and just below 600Z respectively in the three CDTI projects. Liberia has dicided to conduct integrated mapping of NTDs and the country is working on a Plan of Action for a programme for integratefNTD control with CDTI. Given the range of challenges in Liberia, which include CDDs incentive requests, inaccessibility and transportation, a plea was made to APOC to increase financial and technical support to the country. The government remains committed to providing financial support, and in 2009 provided US $20,000 for CDTI activities and $20,000 for cross-border activities. l) Niger: Onchocerciasis is no longer a major public health problem in Niger due to the activities of OCP. The prevalence of the disease which had been 60-70% at the beginning of the programme, with 5% blindness in 1976, is now almost zero. The Government of Niger provided a Uuaget line for the National Onchocerciasis Programme to reinforce community participation to reduce the risk of recrudescence, as for example, from the development of a new dam at Kanadji. It is also necessary to use efficient methods to deal with the disease. Integration of onchocerciasis and LF control is taking place, enabl ing 97 I ,67 6 people in an area of co-endemicity to be treated in 2009 . m) Mali: Onchocerciasis is no longer a public health problem nor does it undermine social development in Mali, however prevalence is still high in some affected communities. Whilst transmission has now been reduced, there is an urgent need to consolidate efforts in order to prevent recrudescence. Surveillance and monitoring activities also need to be intensified. Currently, iDTI is reaching 3500 villages with a therapeutic coverage of g0%. n) Nigeria: Ongoing efforts to control onchocerciasis supported by APOC are yielding positive results in Nigeria. An annual treatment coverage of over 65Yo has been maintained for ttri tast 6 years, although the country is yet to achieve 100% geographical coverage. An exit strategy plan has been developed, however, a major constraint remains due to inadequate government contributions for the implementation of CDTI activities at the State level. An appeal was made to development partners to channel aid towards Nigeria's health needs. JAF16.4 Page 7 o) Sudan: CDTI was launched in 1998, and recently there has been a shift in the mandate of the national programme from control to elimination, in the northern area only. It is anticipated that elimination of onchocerciasis will be possible in the northern area by 2015. Gender representation remains an important element in Sudan, therefore materials that are relevant to women and children have been developed. In terms of capacity building, the programme aims to increase the number of supervisors and volunteers by 35%o,by the end of2010. ln the southern part of Sudan, the importance of controlling onchocerciasis in order to lessen the socio- economic burden is stipulated in Chapter 6 of the Southern Sudan Health policy. A strategic integrated NTD control Plan 2008-2011 is in place, targeting: onchocerciasis, LF, STH, schistosomiasis and Trachoma - using CDTI as a delivery mechanism. In 2008, 2,029,828 people were treated, achieving a therapeutic coverage of 39.lYo and geographic coverage of 70Yo. A total of 4,171 CDDs and 474 health workers were trained. For the first time, onchocerciasis activities will be included in the MoH 2010 budget. JAF was informed that a Multi-NTDs stakeholders meeting will be held in February 2010. p) Tanzania: In line with the development of a five year country plan for integrated NTD control, an NTD Coordinator post was established under the Ministry of Health and Social Welfare, to support co- implementation activities. The country also received financial support of US $703,958 frorn USAID through APOC, for phase one co-implementation of Mass Drug Administration (MDA) for five NTDs, namely onchocerciasis, LF, trachoma, schistosomiasis and STH. Tanzania is commiued to fighting onchocerciasis and in the financial years 2008 and 2009,the government allocated US $121,529 and US $ I 7 4,818 respectively. q) Uganda: Onchocerciasis is endemicin29 out of the 8l Districts, and about 1.5 million people are affected by the disease. Uganda is dedicated to eliminating onchocerciasis and has adopted a multi- pronged programme using targeted vector control and elimination with semi-annual ivermectin treatment. REMO has been completed in 30 villages in 2 post-conflict regions of Northern Uganda and data have been submitted to APOC. With the elimination campaign launched in 2007, there is an urgent need to address the current challenge of cross-border transmission from DRC and Sudan, if Uganda is to achieve its elimination objectives. Thus, an appeal was made to APOC to provide training to technicians from DRC. 26. Following the statements, JAF thanked the Ministers of Health for the updates given regarding the status of onchocerciasis control activities within countries. Given the shift in the programme's focus from control to elimination of transmission where feasible, JAF welcomed the increase in governments' financial contributions as well as their commitment to strengthening national onchocerciasis field and management teams. Furthermore, JAF urged Ministers of Health to explore ways of further increasing government financial allocations for the control of onchocerciasis and other NTDs. The Forum stressed the need for country ownership of CDTI activities as a prerequisite for sustained control. 27. It was also noted that the increased momentum for co-implementation of NTD control highlighted by countries provides an opportunity for an increased role of CDI. In that light, the Forum suggested that APOC explore ways to package and bring to the attention of the Global Fund, the lessons learned from the CDTI mechanism and its subsequent achievements. Potentially, this provides an opportunity to scale up co-implementation using the CDI strategy for the control of NTDs and of malaria. Treatment coverage: presentation by representatives of countries 28. Data on treatment coverage from 15 APOC countries between 2004 and 2008 were reported showing that, overall, geographical coverage increased from 83,404 communities in 2004 to 120,367 in 2008, whilst therapeutic coverage increased from 37.8 million in2004 to 56.7 million treatments in 2008. Both geographical and therapeutic coverage were good in all stable countries except for JAF16.4 Page 8 Equatorial Guinea, in which some urban areas were not treated in 2008. All other stable countries exceeded 65%o therapeutic coverage. Two countries, Chad and Malawi had treatment coverages above 82%. 29. Among the post-conflict countries, geographical coverage remained at l00o/o in Chad and Burundi, and showed significant improvement in Angola and Sudan, but CAR, DRC and Liberia, require further effort. Chad and Burundi also exceeded the 65o/otarget for therapeutic coverage whilst five other post-conflict countries (CAR, Sudan, Angola, Liberia una ORC; *"." b"lo* this threshold. Despite the problems faced by post-conflict countri es, 60%o of them achieved a therapeutic coverage above 65%o. 30. Progress with co-implementation of health interventions for other NTDs alongside CDTI was presented to JAF. Ivermectin treatments were distributed to 120,367 communities in )OOS and g7.2%o of these (104,974) benefitted from additional health interventions. Of the total of 56,716,0:.0 people treated in 2008, 31,507,494 persons from 104,914 communities were provided with health interventions/services for 1l diseases ranging from malaria control to primary eye care. Details of numbers of communities and people treated were given for each disease. Although data was incomplete for some countries, the available data showed that a total of 268,718 CDDs were involved in co-implementation, of whom 21.2% were female. The percentage of females varied considerably from country to country (range 2.5% to 72%). Government Contributions 31. In both 2008 and 2009, overall government contributions to support CDTI activities, equipment and salaries amounted to US $25,543,341 and US $26,645,576 respectively. Out of this amount, US $784,919 was invested in health education, sensitisation, advocacy and mobilisation in 2008; a total budget of US 5661,739 was allocated for these activities in 2009. h was noted that NOTFs advocated for sustainable financing and that the 2009 disbursed funds had been distributed as follows: 3J%o towards sensitisation, 33Yo towards health education and 30%;o towards advocacy. Evidently, sustainable financing of CDTI makes it possible to control or eliminate onchocerciasis in Africa and makes the control of other health interventions possible at low cost. 32. Following the presentation, JAF noted that government financial contributions indicate increasing support to onchocerciasis control, especially in the context of NTD control budget lines. JAF requested that, in future meetings, a complete picture of allsources of support for implementation of CDTI is provided, including from governments, NGOs, APOC and other potential donors. This will facilitate estimation of total programme costs and help identifo current and potential future funding gaps as APOC implements its exit strategy. As CDTI is increasingly integrated into health systems foi co-implementation, it should be noted that it becomes more difficult to breakdown costs by individual diseases. Report of the Technical Consultative Committee (TCC) 33. Professor Adenike Abiose, Chair TCC, presented reports of the last two TCC meetings which were held in March and September 2009. TCC noted APOC's achievements in continuing collaboration with NGDO, and other disease control partners in co-implementation activities. TCC endorsed these actions, however, they advised that co-implementation should take place using the CDTI platform to ensure that onchocerciasis control is not compromised. APOC was commended for its committed leadership and was urged to continue its support to countries to enable them to move from control to elimination of transmission where feasible. TCC commended Nigeria and Cameroon for setting up Technical Review Committees. During 2009, TCC continued to provide guidance to APOC on strategic, technical and research issues, the review of annual technical reports and country visits by TCC members to support CDTI. On technical issues, the report of the Informal Consultation on the Elimination of Onchocerciasis where feasible was received by TCC. TCC commended Uganda on their elimination efforts and encouraged APOC to provide Uganda with the necessary support and JAFI6.4 Page 9 information. With regard to research activities, TCC received updates on the moxidectin trial and expressed concern that the completion of the trialwas less likely to occur before APOC's exit in 2015. An update was also received by TCC on the rapid assessment of Loa /oa (RAPLOA) carried out in 7 APOC countries. Lastly, TCC approved 4 out of 7 research proposals received in 2009, three of which were from Cote d'Ivoire, which submitted for the very first time. Sub-regional Ministerial meeting on cross-border collaboration 34. ln response to the call of JAFI4 to strengthen cross-border collaboration, a meeting was held in Ouagadougou from 29 September to I October 2009 for West African countries. The meeting was attended by more than 100 participants, 5 of whom were Ministers of Health, including l2 delegations (Benin, Burkina Faso, Cote d'lvoire, Ghana, Guinea, Guinea Bissau, Mali, Niger, Nigeria, Senegal, Sierra Leone and Togo). The main objectives of the meeting were as follows; to review progress achieved thus far on integrated surveillance activities in l3 countries; and to strengthen collaboration both among and within countries. During the meeting, 20 diseases were identified for surveillance, including onchocerciasis, other NTDs and endemic diseases such as meningitis and polio. Some challenges were also identified, including; the absence of a framework for consultation and information-sharing across borders - surveillance activities were unable to cover all areas especially at borders; limited numbers of qualified personnel, laboratories, funds and limited community participation despite efforts being made. Following the meeting, documents were prepared aimed at building institutional capacity for cross-border epidemiological surveillance and control. It was also decided that national funds be provided within countries for cross-border activities. A key outcome of the meeting was an agreement to request WAHO to submit recommendations of the meeting to ECOWAS to allow for budget strengthening. The countries agreed to hold an annual meeting on surveillance. 35. A second cross-border meeting was held in Cameroon from 12-14 October 2009, was attended by Angola, Cameroon, Equatorial Guinea, CAR, Congo, DRC, Chad, representatives from WHO. APOC, and development partners. Specific objectives were to present the NTD situation in the region as a first step in strengthening and building strategies to increase cross-border NTD control activities, and to increase surveillance of polio. The following key challenges were highlighted; absence of sub- regional consultation on NTDs, and insufficient epidemiological surveillance information. The meeting's outcomes included the development of plans for integrated mapping of NTDs, some of which are already underway in some countries. Recommendations were also made to establish the sub-regional level epidemiological disease status; and to strengthen and harmonise strategies for onchocerciasis and NTD control. 36. Following the presentations, JAF agreed that there was a continuing need for cross-border collaboration for NTD control, especially for onchocerciasis, and that this need will continue post- APOC. The Forum therefore encouraged Ministers of Health to continue engaging in sub-regional meetings to improve disease control outcomes. Furthermore, JAF recognised the importance for APOC to maintain a lead role in establishing sustainable sub-regional cooperation, which will be essential even after the closure of the programme. Status of onchocerciasis transmission in Africa 37. At the closure of SZ in December 2009, APOC made technical help available to these countries. Currently CDTI, using one annual treatment, achieves geographic and therapeutic coverages of 100% and 80-85% respectively; treating l0 million people in ex-SIZ countries in 2008. The activities carried out are CDTI, epidemiological evaluations and co-implementation of control of onchocerciasis with that of other NTDs. Overall, the geographical coverage was 100% in stable countries, however, in post-conflict countries geographical coverage was lower, for example - Guinea (80%), Cote d'Ivoire(20%o), Guinea Bissau (50%).In most cases CDTI activities had been halted in these post-conflict countries, although ivermectin distribution has now resumed. JAFI6.4 Page l0 38. With regards to ex-OCP countries, epidemiological evaluations undertaken in seven countries, showed that all the sentinel villages had infection rates of 5%o or below. Whilst, between 2004-2007 an upsurge in prevalence was observed in three communities in Ghana, prevalence has now declined, Currently, epidemiological activities are underway in Mali, Senegal, Guinea Bissau, Benin and Niger. Results from Togo, Ghana and Cote d'lvoire were unsatisfactory, because of continuous transmission in these areas, for which reason, APOC had provided increased support. Co-implementation is also being conducted in some ex-OCP countries. ln conclusion, the entomological situation is satisfactory in most ex-OCP countries, for which indicators have been kept below 5%. This is important in order to prevent recrudescence. Elimination of onchocerciasis transmission in Africa, where feasible 39. Dr Hans Remme, presented the report of an lnformal Consultation on Elimination of Onchocerciasis Transmission in Africa, and the results of evaluation studies undertaken in 2009, that indicated that elimination of onchocerciasis transmission and halting of ivermectin treatment without recrudescence could be a realistic target, at least in some parls of Africa. Scientific evidence from selected foci in Senegal and Mali, was published in an international Journal in July 2009, showing that elimination of onchocerciasis control using ivermectin alone is feasible. 40. Following the presentation, JAF noted with satisfaction that the Informal Consultation had been held at APOC HQ and was pleased to receive the report of this meeting. JAF endorsed APOC's efforts to evaluate progress towards elimination in its' CDTI projects and encouraged continuation of these efforts in the coming years. JAF also encouraged APOC to investigate alternative strategies to accelerate progress towards elimination of transmission of infection in trouble-spots, for example by using multiple treatments per year or alternative interventions. Furthermore, as APOC moves from control to elimination where feasible, JAF endorsed further mapping to identifu transmission zones and possible additional target areas for treatment. Lastly, JAF asked that APOC management address other recommendations made by the informal consultation. Co-implementation in Tanzania 41. ln 2007, Tanzania developed a five-year integrated NTD control plan, which has been implemented in 36 districts within five regions. APOC and USAID provided a total of US $703,958 to support phase one activities and an NTD Coordinator post was established at the Ministry of Health and Social Welfare (MoHSW), in order to support country-wide co-implementation activities. [n 2009, therapeutic coverage with ivermectin and albendazole was greater than 80% and CDI proved an effective strategy for delivery of multiple health interventions. Challenges encountered during the MDA in 2009, included: the need to coordinate different approaches (school-based vs. CDI), human resource and managerial issues for combined multiple interventions, the need for increased financial resources and an unforeseen outbreak ofcholera in one Region. 42. JAF decided that APOC should contribute financially and technically to country-led co- implementation efforts to control onchocerciasis and other NTDs using CDTI. JAF recognised the value of the CDTI strategy, for both ivermectin treatment and as a vehicle for delivery of other health interventions and commodities and for strengthening health systems. Therefore, JAF decided that APOC and its partners should ensure that CDI is embedded in national health systems to ensure sustainability of the strategy after ivermectin treatment stops and before APOC phases out. lntegration of CDI into national health systems will strengthen them from the bottom up, and deliver improved primary health care at the community level. 43. Lastly, in order to allow for specific comparisons of the costs and benefits of controlling and eliminating onchocerciasis with the costs and benefits of co-implementation with other interventions, JAF decided that obtaining cost analysis data would be desirable in several respects, especially in comparing costs and benefits of multiple disease interventions using CDI. APOC and the World Bank should take the lead in exploring means of obtaining more accurate and specific data. JAFI6.4 Page 1 1 Statements by Partners Pfizer 44. Following the recent acquisition of Wyeth by Pfizer Inc., Dr Pol Vandenbroucke, Vice President for Development of Emerging Markets of Pfizer, addressed JAF and confirmed the commitment of Pfizer to continue clinical development of moxidectin. He expressed Pfizer's hope to prove the efficacy and safety of moxidectin as part of their efforts to make Africa river blindness free. USAID 45. Increased involvement of USAID in NTD control, starting in 2006, followed recognition by the US Congress of the opportunity to focus on integrated NTD control as a means of achieving cost- effective increases in treatment coverage. The funding represents an unprecedented level of support for NTD control and an opportunity for expanding this programme. The five targeted diseases are; lymphatic filariasis, onchocerciasis, trachoma, soil-transmitted helminthiasis and schistosomiasis. USAID currently supports NTD control through co-implementation with CDTI in South Sudan, Burkina Faso, Democratic Republic of the Congo, Tanzania and Cameroon. USAID funding is intended to supplement or complement that of other donors; working with them to fill gaps that have been identified in order to increase treatment coverage. The present adrninistration announced a new health initiative of which NTDs are a component. It is planned to expand the existing programme for which the US $15 million initially allocated for 2006-8 was subsequently increased to US $25 million in 2009. The amount to be allocated for 2010 has not been announced but may increase significantly. A new strategy for NTD control is being developed in view of the increased funding, which will include integrated programmes and scaling up of the key elements of MDA, including mapping. Countries are requesting assistance from USAID for morbidity control and improved sanitation and these will be incorporated into the new strategy. In conclusion, this is an exciting time to build on existing achievements for NTD control. Steps to be taken include the development of costed NTD national plans, mapping of disease programmes and accurate forecasting to enable sufficient quantities of drugs to be made available fortimelytreatmentof populations. The new administration is expected to push for elimination of lymphatic filariasis. CIDA Canada 46. CIDA has supported onchocerciasis from the establishment of the Onchocerciasis Control Programme in 1974. Canadian aid is now focussing on the development of a new model for strengthening primary health care (PHC). In 2006, the Canadian Prime Minister announced an initiative for strengthening PHC in Africa, development of human resources, equity in delivery of services and research in public health and health systems. CDTI is considered to be a highly appropriate approach for pursuing this initiative. World Bank 47. The World Bank has endorsed its approach for engaging in the health sector through health systems strengthening for which the Bank has a comparative advantage. The Bank continues to assist lower and middle income countries with control of malaria, HIV/AIDS, TB and onchocerciasis. The board of the Bank is shifting emphasis towards assisting in strengthening health care systems. In line with that new strategy, funds have been allocated, half of which are being provided for results-based funding, for which successful schemes have been initiated. The Bank is now looking to see how APOC can be oriented towards health systems strengthening. APOC is increasing its strength on the system side, especially with delivery systems where these are complementary to the overall health system. The APOC approach involves primary health care from the bottom up and this concept has energised the World Bank President, who is now enthusiastic to involve APOC in this area. There is now a need to develop a systems approach for NTD control and to formulate a longer-term strategy for APOC to implement NTD control at the community level. JAFI6.4 Page 12 Belgium 48. In order to address some of the gaps in the delivery of primary health care in Africa, we need to look at the potential of onchocerciasis control to provide a more general approach to the delivery of health services. To provide this requires a discussion on APOC positioning based on either a project or programmatic approach. DFrD (UK) 49. In September2009, the UK Government committed €50 million forNTD control. Some of these funds have been channelled through the Carter Center and some provided for procurement of drugs for control of schistosomiasis and STH. Centre for Neglected Tropical Diseases (CNTD), Liverpool 50. Professor Moses Bockarie, the new Director of CNTD, announced the receipt of [10 million from DFID and GSK for activities related to NTD control. The Liverpool Centre for Neglected Tropical diseases now has a mandate beyond lymphatic filariasis and will expand its focus on training to support six countries and research laboratories for NTD surveillance. The Centre has made a call for fellowships and supports regional workshops for training and monitoring and evaluation. Support for operational research and integrated control based on the CDI strategy will also be increased. Training of CDDs 51. The number of CDDs newly trained or re-trained increased from 147,202 in 2004 to 405,552 in 2008, of whom 277,679 were retrained and 127,843 newly trained. The number of health workers trained increased from36,404 in2007 to 39,556 in 2008 of whom 25,537 were retrained and 13,919 newly trained. 52. Following the presentation, it was noted that progress is being made with gender- mainstreaming within the APOC programme, particularly in the training and retraining of CDDs. Opportunities were identified for improving the reporting of such activities by disaggregating existing and future data, by gender. JAF urged APOC to continue mainstreaming gender throughout its activities and to repoft on this aspect at future JAF meetings. 53. The need for Information, Education and Communication (IEC) materials produced in national languages to facilitate and strengthen the work of country Programmes was discussed. To this end, JAF agreed that the APOC Trust Fund should be used to produce IEC documents in national working languages to satis|, specific country needs. Outcome of the closed door sessions 54. Separate closed-door sessions of African Health Ministers, Donors and NGDOs were held with the following outcomes: Statement by Ministers of Health 55. The closed session of Ministers discussed three agenda items: l) Cross-border collaboration and setting up of a Ministerial sub-committee, 2) National ownership and financing CDTI projects and 3) Financial support to elimination of onchocerciasis transmission in areas where feasible. The Ministers' made the following recommendations to JAF: (i) a sub-ministerial committee was not needed; rather, cross-border activities on onchocerciasis should be taken up by a technical committee that would meet and prepare a report for JAF and that report would be used to brief Ministers during closed sessions; (ii) that CDTI is a very useful and effective model strategy taking into consideration a JAF16.4 Page 13 bottom up, grass-roots approach, and donors should continue to provide technical and financial support to strengthen capacity building and national ownership of CDTI projects; (iii) The Ministers reaffirmed their commitment to increase their budget and to the fight against onchocerciasis. 56. Following the statement of Ministers of Health, JAF approved all the recommendations from the Ministers, including the request for APOC to extend financing to all projects in Cameroon up to 2015. Statement by NGDO Group 57. The closed session of the NGDO Group discussed the following issues: sustainability of the ivermectin programme, the responsibility of governments to address challenges related to the motivation and incentives for CDDs work; the challenge of maintaining the principles of CDTI where school-based treatments are also given; the need to develop integrated packages of training and the need to strengthen monitoring systems to ensure that CDDs appropriately apply the skills learnt. 58. Following the statement of the NGDO Group, JAF thanked the Group for their continued support to the communities and countries and urged Governments to address the issues related to incentives for CDDs. Statement by Donors 59. Donors feel that national ownership is a necessity in order to ensure programme sustainability. Countries are encouraged to extend national ownership and to find means of assessing Health strengthening metrics. Yearly progress reports should be provided that are linked to specific targets and objectives. 60. Following the statement of donors, JAF decided that APOC should undergo a mid-term external evaluation of the programme in 2010. Lastly, JAF thanked the donors for their unwavering suppolt and commitment to the programme Health Impact Assessment of APOC operations 61. Professor, Dik Habbema from the Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, the Netherlands, presented an update of the health impact of APOC to JAF, including calculations on the burden of the disease in Disability Adjusted Life Years (DALYs). In 2008, the geographical coverage of APOC programmes increased by 1.4% to 82.2o/o from2007 figures. However, a slight decline was observed with the therapeutic coverage which fell from 62.5% in 2007 to 61.2%o in 2008. Based on simulated trends in prevalence of infection and disease, the number of prevented disease cases in APOC countries in 2009 were: lnfection - 24 million, Itch - 12,000 and Low vision or blindness - 400,000. The loss of more than 1 million DALYs was prevented by APOC in 2008. 62. Data on the funding of OCP/APOC and its impact were also presented. On average, the donor contribution to OCP/APOC is $30 million per year, and in 2008, just under $15 million (0.5% of total donor aid to health) was received by APOC from donors for onchocerciasis activities. During the same year, treatment cost was $0.25 per person. Erasmus and APOC activities for 2010 include;the revision of the ONCHOSIM software, which is now 20 years old; validation of model predictions against trends in epidemiological data, and the provision of HIA at project level. Additionally, an analysis of the synergetic effects of co-implementation of interventions, both in terms of costs and benefits, would be essential. JAFI6.4 Page 14 Report of the NGDO Coordination Group for Onchocerciasis Control 63. Dr Tony Ukety, Coordinator of the NGDO Coordination Group for Onchocerciasis Control, presented the annual repoft of the Group. During the year under review, the Group continued to provide managerial, technical, and financial support to APOC, ex-OCP countries and the Onchocerciasis Elimination Programme for the Americas (OEPA). Dr Ukety, informed JAF that in March 2009, the Malaria Consortium and the lnternational Agency for the Prevention of Blindness (IAPB) joined the NGDO Group as 'member' and 'associate member' respectively, bringing the total number of NDGO 'members' to l5 and 'associate members' to 3. He also highlighted the outcome of an event of this Group which was held on 8-10 September 2009 in Accra, Ghana, in conjunction with the International Coalition for Trachoma Control (ICTC) and the Lymphatic Filariasis Non- Governmental Development Organizations Network (LF NGDO Network). The main outcome of this meeting was the establishment of the 'Non-Governmental Development Organisations Neglected Tropical Diseases Network' (NGDO NTD Network), and subsequently the nomination of Dr Adrian Hopkins, Director of the Mectizan Donation Program and Mr. Simon Bush, Director, African Alliances & Advocacy from Sightsavers International, as Chair and Vice-Chair respectively, of the Network on a two year term. 64. JAF received the report with thanks and commended the NGDO Coordination Group for Onchocerciasis Control for their continued support. Update from the Multi-Disease Surveillance Centre (MDSC) 65. Professor Evariste Mutabaruka, acting Director, MDSC, informed JAF of the proposal to turn MDSC into a Centre of excellence that was discussed in July 2009 by ECOWAS Ministers. MDSC is collaborating with regional training centres in order to improve availability of qualified laboratory technicians and managers trained in modern diagnostic techniques and quality assurance systems. Such a regional disease surveillance system would provide a platform for policy harmonisation, cross- border collaboration, coordination of response to trans-boundary epidemics, capacity building, experience sharing and resource mobilisation. Professor Mutabaruka appealed to donors and partners for additional funding to enable the Centre to achieve its goals and objectives. 66. JAF noted the information provided and congratulated MDSC on this development. Current research within APOC and TDR collaboration 67. Dr Annette Kuesel, from TDR, gave an update on the ongoing development of Moxidectin, which is being conducted in collaboration between WHO and Pfizer, USA. Phase two studies have now been completed in Ghana on 172 ivermectin naive subjects, and final data will be available in the second quarter of 2010. In Liberia, studies commenced in April 2009 and 156 subjects have been treated to date. In DRC, approval from the Ministry of Health was received in December 2009, which led to the initiation of the study in the same month. Dr Kuesel highlighted the importance of preventing delays in Phase three, which would otherwise cause a number of problems including: the advancement of CDTI into the study area; insufficient ivermectin-naive subjects for study; delays in decisions on moxidectin provision to Africa, and increased development costs. The next step for the project is to conduct community studies on about 40,000-80,000 subjects, in countries that are yet to be identified. 68. Other completed studies include; firstly, the examination of the effect of early treatment with albendazole and diethylcarbamazine on progression of LF (Brugia malayi) pathology in 3-15 yr old children. After, six 6-monthly treatments with 400 mg Albendazole plus 6 m{kg Diethylcarbamazine, results from 94 subjects (children) showed cleared microfilaraemia in 100% (32132) of subjects; relieved early lymphoedema in 75%o (3/4); and reversed lymph vessel dilation in 89.6%o (69177). Secondly, a study on the effect of bimonthly treatment with albendazole on Loa loa microfilaremia JAFI6.4 Page 15 conducted in Cameroon, showed that albendazole treatment does not decrease Loa loa microfilaremia sufficiently. Lastly, was the development by TDR of a tool to monitor ivermectin efficacy. 69. Following the presentation, JAF noted that current data suggest that elimination of onchocerciasis where feasible using CDTI with annual distribution would take more than l0 years of continuous high treatment coverage. The possibility of twice-yearly ivermectin treatment expediting progress towards elimination compared with the standard single annual treatment was raised. Twice- yearly treatment may effect this sooner, but current studies have yet to provide scientific evidence to justifu twice-yearly treatment as a better approach in APOC countries. Therefore, JAF urged APOC, TDR and TCC to determine if twice-yearly treatment hastens elimination and shows benefits over annual treatment in health impact and overall cost. Further studies on Moxidectin should be accelerated and results should be made available as early as possible. Audit Report 70. The Forum took note of, and accepted, the Auditor's report, read by the Legal Counsel of WHO. Atldendum to Plan of Action and Budget 2008 - 2015 71. During JAF 14, the Forum had noted that additional funding would be required by APOC for implementation of the expanded activities for the period 2010-2015, especially in consideration of the increased demands for co-implementation of NTD control with CDTI. APOC presented to JAF l5 an indicative supplementary addendum for the period 2012-2015.It was emphasised that this was an indicative budget and that following further consultation with partners, APOC management would submit a detailed document with a revised budget taking into account the needs of countries for 2012- 2015 to be received by JAF, 30 days before JAF 16. The areas expected to be covered in next years' submission include; strengthening health systems, moving towards elimination of onchocerciasis transmission where feasible, co-implementation of NTD control with CDTI, human resource development and management. Plan of Action and Budget for 2010-2011 72. JAF approved the Plan of Action and Budget for 2010-201 I and the corresponding budget for the amount of US $57,415,000. [t was reported that budgetary planning had shifted from annual to biennium budgets in accordance with the GSM system. The budget has increased, mainly due to up- scaling of activities in post-conflict countries, expanding co-implementation to 62 CDI projects, strengthening research on surveillance markers, strengthening staffing, and strengthening of health systems. 73. Following the presentations of the audit report, addendum to the PAB and the financing of APOC, the following points were raised during the plenary discussion: (i) The issue of cross-border activities in all sub-regions was discussed as was the equitable distribution of funds across countries and regions. APOC management reminded JAF that cross-border issues are paft of the strategic plan (page 9) in which it is stated that APOC will promote and co-finance Ministerial and cross-border meetings and this was done in 2009. Distribution of funds to countries is based on needs; funding to post- conflict countries and central Africa has therefore increased, whilst ex-OCP countries do not receive disproportionate funding but receive what is essential to maintain the benefits achieved by OCP. JAFI6.4 Page 16 (ii) (iiD (iu) (v) (vi) (vii) Concern was expressed that there may still be under-budgeting, given the move towards elimination of transmission where feasible and the need for improved diagnostic tools and additional operational research. The need for clearer concepts for post-treatment surveillance was noted. It was also recognised that the CDTVCDI strategy has been a highly significant development for health system strengthening, however,-where health systems are weak parallel systems may be set up and FLHF need some support. The clear goals of the PAB were commended but the percentage (17%) for administrative costs was questioned. APOC management explained that this had previously been between l}-llYo, but had risen largely because of the need to increase support to the 7 post-conflict countries. In these countries, following recommendations of TCC and with CSA approval, APOC provided experienced field people as Technical Advisers to work with their Ministries of Health and NOTFs. Furthermore, country visits by TCC members, recruitment of consultants and increased staffing at APOC Hes had increased costs. Additionally, APOC is recruiting epidemiologists, a health system specialist and a person to take responsibility for co-implementation. An additional point of discussion was the possible advantage for APOC to move from a project to a programmatic approach that might ease the administrative burden and fit better into National plans for co-implementation. This could also allow APOC to concentrate more on organisationaltasks and M&E. The issue of APOC moving from control to elimination of onchocerciasis transmission where feasible was discussed. It rvas noted that this had financial implications and that because of the inadequate knowledge of the epidemiological heterogeneity throughout endemic countries it was important to be aware that elimination may not be feasible or cost effective in all areas. In relation to this, there is a need for improved diagnostics and surveillance. APOC was commended for efforts towards gender mainstreaming and it was noted that AfDB is now working closely with APOC in this area; however, there is need for a mechanism to ensure that women are engaged in elimination of infection. APOC management agreed to include in the budget the request to document "best practices" for Community-directed interventions. The ability of NGOs to take over responsibility for supporting CDTI projects following APOC's withdrawal of funds would depend upon their ability to raise funds and this could not be guaranteed. Financing of the African Programme for onchocerciasis control (Apoc) 74. Dr Ok Pannenborg introduced Dr Don Bundy, formerly a Professor at Oxford University, UK, who will be taking over as the World Bank's Onchocerciasis coordinator following Dr Pannenborg's retirement. It was noted that APOC is one of the largest partnerships in public health in terms of scope, financing and duration. The World Bank, as fiscal agents of APOC, would like the tenure of this role to be marked by transparency and will be indicating resource flows on its website along with financial forecasts and projections. A second characteristic is due diligence with respect to the fiscal aspect including costs and resource flows. APOC is one of the largest players in terms of regional activity in public health. Regarding its financial history, the cumulative costs of OCP and APOC since 1974 total US $ l. I billion. This shows that the scale of investment is now plateauing, which is a good thing as it indicates increased cost efficiency. [n terms of total receipts, the resource flows of the first and second phases of APOC show a consistent upward trend. The earlier NGDO presentation showed that its conhibution was US $5-6 million so the actual resources are at least 50%o greater. It was stated previously that the contribution of Governments was US $25 million, which also makes the total substantially higher. As part of the APOC team, the Bank would like to consult with NGDOS about their contributions and move towards results-based financing according to the numbers of people treated. The maps showing the shrinking of onchocerciasis distribution produced by APOC and TDR are impressive, demonstrating how the investment in APOC is really translating into health improvements. The Strategic Plan and Budget of APOC is being used as the target for financing. JAF l4 had determined that we were 20%o behind for this plan; this does not include NGDO or Government JAF16.4 Page 17 expenditure. Expenditure in 2008 and 2009 is more or less on target and there is more to be disbursed in 2009. The Bank thanked the 20 donors for their patience in working through the funding mechanisms and for their contributions. Based on current pledges and receipts the programme is fully funded and has a cushion of funding for 8 years. Major new challenges that are not costed include the NTD agenda, activities in DRC and the need to respond to challenges of post-conflict countries. Based on the indicative budget of around US $60 million, forecasting shows that additional pledging that has been discussed with new donors comes to between $34-42 million, so there will still be a shortfall of $20 million but there are other donors that are likely to provide funding if NTDs and health system strengthening are among the goals. 75. In discussions it was suggested that for health system strengthening and new funding initiatives from USAID and DflD, it would be timely to have an independent evaluation of APOC. Donor Pledges 76. The international donor communify reaffirmed their commitment to onchocerciasis control in Africa, with new and additional pledges: a) Kuwait Fund: The Kuwait Fund has been contributing to Onchocerciasis control since 1974 and will continue making contributions up to 2015. For the coming year the contribution is US $1.5 million. b) Kingdom of Saudi Arabia: Saudi Arabia has supported OCP from the beginning and subsequently APOC, and will continue supporting the programme to the end with the sum of US $43 million. The Kingdom of Saudi Arabia supports the PAB for the coming year and pledges the sum of US $2 million for 2010-2015. c) DFID: The United Kingdom has pledged f50 million for NTD control up to 2014 and will continue to support APOC. For the coming year DFID will give f500,000 for ongoing APOC activities. d) Canada - CIDA: Canada will continue to finance APOC between 2009 and 2015. Canadian dollars $4.5 million have already been given in2009 and $2.4 million will be disbursed in 2010. e) World Bank: The World Bank is pleased with APOC proposals and in its capacity as donor rather than as fiscal agent will give US $2 million for 2009-2010 and will continue to do so for 2010-201I in line with APOC's mandate for CDTI and expanded mandate for NTD control. 0 USAID: This year USAID awarded a new grant with a ceiling of US $25 million for the period 2008-2015 and will provide $2 million to APOC in 2010. USAID noted the highly successful collaboration with APOC over the years. g) Merck & Co., Inc.: At JAFI3 Merck pledged US $25 million for the period 2008-2015 and for 2010 willcontribute $3.125 million to the trust fund. h) NGDO Group: The NGDOs do not support the APOC trust fund financially but reconfirmed their commitment at current levels. The group has grossly underestimated their contributions to APOC and this will be fully acknowledged at a later date. i) Belgium: The contribution of Belgium for 2010- I I will be €400,000 per year. j) Netherlands: Like Belgium, the Netherlands makes a multi-year conhibution and has already given €2 million and will give the same amount of €2 million in 2010. After 2011 it is not likely that the Netherlands contribution will grow but the country will, nonetheless, continue to support APOC. JAFI6.4 Page 18 k) African Development Bank: The African Development Bank made a pledge in Brussels and that funding was approved for 2008-2015, and disbursement of funds had begun in 2008-9, and will continue as planned to the tune of l5 million units of account, which is approximately equal to US $23 million. 77. Following the pledges, APOC management on behalf of the beneficiary communities, expressed their profound appreciation for the donations and reassured the donor countries and institutions, of the programme's commitment to the elimination of onchocerciasis in Africa. Other matters Special tribute to champions of onchocerciasis control 78. JAF acknowledged the dedicated contributions to APOC and onchocerciasis control in Africa made over many years by Dr Ok Pannenborg, World Bank, Dr Hans Remme, former WHO/TDR, Dr Claude-Henri Vignes, former WHO Legal Counsel and Professor Allan Foster, CBM. Date and place of JAF16 79. At the kind invitation of the Federal Govemment of Nigeria, the l6thsession of JAF will be held in Abuja, Nigeria. Dates will be communicated to JAF members in the coming months. Review of Final Communiqu6 80. The Final Communiqud was reviewed and adopted. Closure of the Fifteenth JAF Session 81. In her closing remarks, Dr Amazigo, on behalf of the onchocerciasis affected communities, thanked the donors, governments and the NGDOs. She reiterated that APOC would under-go a mid- term external evaluation of the programme in 2010, as requested by the donors. Finally, DrAmazigo thanked the AfDB, in particular Dr Ilunga for organising JAF 15. 82. The chairman commended participants for the quality deliberations during JAF 15, and the development partners for their dedicated commitment to onchocerciasis control activities. He called upon fellow Ministers of Health to intensi! advocacy activities and to consult with their respective heads of government, as a way of strengthening political will and commitment towards fighting onchocerciasis. Lastly, the Chair thanked the Government of Nigeria for extending the invitation to host JAF 16. JAFI6.4 Page 19 Annexes JOINT ACTION FORUM Office of the Chairman JOINT ACTION FORUM Fifteenth session Tunis. Tunisia. 8-10 Decenrber 2009 Annex I African Programme for Onchocerciasis Control (APOC) Programme africain de lutte contre I'onchocercose JAF-FAC FORUM D'ACTION COMMUNE Bureau du Prdsident ORIGINAL: ENGLISH December 2009 LIST OF PARTICIPANTS/LISTE DES PARTICIPANTS APOC COUNTRIES/PAYS APOC Burundi 01. Dr Emmanuel GIKORO, Ministre de la Sant6 Publique, B.P. 1820 Bujumbura, Rdpublique du Burundi - Tel: (+257) 22229195 - Fax: (+257) 22229196- Email: egokoro2OO l@yahoo.fr 02. Dr Norbert BIRINTANYA, Directeur G6ndral de la Sant6 Publique, Ministdre de la Santd Publique, B.P. 1820, Bujumbura, Rdpublique du Burundi - Tel: (+257) 177132134; (+257) 22242542 - Fax: (+257)22229196 - Email : birintanya@yahoo.fr 03. Dr On6sime NDAYISHIMIYE, Coordonnateur National du Programme ( Maladies Tropicales N6gligdes >, Minist,ire de la Sant6 Publique, B.P. 3128, Bujumbura II, Rdpublique du Burundi - Tel: (+2571777735102 - Fax: (+257) 22229196 - Email: ndayones@yahoo.fr 04. Dr Didace MBARIRIMBANYI, Coordonnateur National, Programme National de lutte contre I'Onchocercose, B.P. 1820, Bujumbura, Burundi - Tel: (+257) 22249333; (+257) 22249334 - Fax: (+257 ) 22229 I 9 6 - Email : mbarididace@yahoo.fr; pnlobu rund i@yahoo. fr Cameroon/Cameroun 05 Monsieur Andrd MAMA FOUDA, Ministre de la Sant6 Publique, Yaound6, Cameroun - Tel (+237) 22 220-172 - Fax: (+237) 22 220-233- Email: andramama@yahoo.fr Professeur Gervais ONDOBO ANDZE, Directeur de Ia Lutte contre la Maladie, Prdsident du GTNO, Ministdre de la Sant6 Publique, Yaound6, Cameroun - Tel: (+237) 2223 93 48 - (+237); L.D.: (+237) 22 23 33 84 - Cellulaire: (+237) 99 86 44 0l - Fax: (+237) 22 22 44 19 - Email: andzegervais@yahoo. fr Dr Marcelline Doroth6e NoEl NTEP, Coordinateur du Programme National de lutte contre l'Onchocercose/ Secrdtaire Ex6cutif du GTNO, Ministdre de la Sant6 Publique, Yaound6, Cameroun - Te[/fax: (237)22226-910 - Cellulaire: (+237) 99 8l 08 0l; (+237) 77 30 0l 60 - Emai I : s goa@camn et.cm; man gamar200 1 @yahoo. fr 06 07 JAFI6.4 Page 20 Central African Republic/R6publique Centrafricaine 08. M. Andrd NALKE DOROGO, Ministre de la Sant6 Publique, de la Population et de la Lutte contre le Sida, B.P. 883, Bangui, R6publique centrafricaine) - Tel: (+236) 21 61 47 29 (direct) et (+236) 75 505417 - Fax: (+236) 21 61 27 49 - Email: analkedorogo@yahoo.fr 09. Dr B6noit KEMATA, Coordonnateur National du Programme National de Lutte contre l'Onchocercose, Ministdre de la Santd Publique, de la Population et de la Lutte contre le SIDA, B.P. 1772, Bangui, R6publique Centrafricaine, T6l.: (+236) 70 40 26 0l; (+236) 72 77 46 75; slc WR (+236) 21 61 0137 - Email: bkernata@-vahoo.fr Chad/ Tchad 10. Dr NGOMBAYE DJAIBE, Ministre de la Santd Publique, B.P. 440, N'Djamena, R6publique du Tchad - Tel: (+235)2515 I 14- Fax: (+235) 6291637 - Email: diaibe lt@vluqa.lt 1l Dr Ndeikoundam NGANGRO MOSUREL, Directeur G6neral des Activitds Sanitaires, Ministdre de la Sant6 Publique, B.P. 440 N'Djamena, R6publique du Tchad - Tel: (+235) 2 52 28 66 - Email : ndeikourndam@-vahoo. fr t2 Mr. Hassane SALIM, Directeur de Cabinet du Ministre de la Sant6 Publique,8.P.440, N'Djamena, Rdpublique du Tchad - Tel : (+235) 6291637 - Email : hphas@yahoo.fr 13 Dr Dadjim BLAGUE, Directeur Systdme de Sant6, Ministdre de la Sant6 Publique, B.P. 440, N'Djamena - R6publique du Tchad - Tel: (+235) 6348952 - Email: dadjimb@yahoo.fr t4 Dr Mahamat Saleh YOIINOUS, Secr6taire Gdndral du Ministdre de la Sant6 Publique, B.P. 440, N'Djamena, R6publique du Tchad - Tel: (+235) 6293614 - Email: rnsyounoussi@yahoo.fr' 15 Monsieur Lokemla NADJILAR, Coordonnateur National du Programme de Lutte contre l'Onchocercose (PNLO), B.P. 440 N'Djamena, R6publique du Tchad - Tel (+235) 629 0l 64; (+235) 913 38 96 - Fax: (+235)252 48 38 - Email: nadjilar@yahoo.fr 16. Mr. Akouna B6noit PIRCOLOSSOU, Chef de Canton, Bayaka, Region Tandjile, Rdpublique du Tchad Republic of CongoiR6publique du Congo 17. Prof. OBENGUI, Directeur de l'Epid6miologie et de la Lutte contre la Maladie, Ministdre de la Sant6 et de la Population, Direction de l'Epid6miologie et de la Lutte contre la Maladie, Brazzaville, R6publique du Congo - Tel: (+242) 5563544; (+242) 4202580 - Email: docteur_oben gi @yahoo. fr 18. Dr Frangois MISSAMOU, Coordonnateur National du Programme National de Lutte contre l'Onchocercose (PNLO), Ministdre de la Sant6 et de la Population, Direction de l'Epid6miologie et de la Lutte contre la Maladie, BP 1066, Brazzaville, R6publique du Congo - Tel: (+242) 52549 4l; (+242) 6680563 - Email: opc_congo@,vahoo.fr Democratic Republic of the Congo/R6publique Ddmocratique du Congo 19. Dr Fortunat TSHITOKA NTUMBA TUDIK, Superviseur National, Programme National de Lutte contre l'Onchocercose (PNLO), Ministdre de la Santd Publique, Avenue de la Justice, no 36, Kinshasa-Gombe, R6publique Ddmocratique du Congo - Tel: (+243) 994 538 960; Qa3) 813395626 - Email : dfntumbacito@)uahoo.fr 20 JAFI6.4 Page 2l Equatorial Guinea/Guin6e Equatoriale Dr Anacleto SIMA NSUE, Directeur National, Programme Onchocercose et Autres Filariose, Ministdre de la Sant6 et du Bien-Etre Social, Malabo, Guinde Equatoriale - Tel: (2a0) 232620 21. Dr Rufino NGUEMA ANDEME, Technicien, Programme National de Lutte contre l'Onchocercose (PNLO), Ministdre de la Santd et du Bien-Etre Social, Malabo, Guinde Equatoriale - Tel: (240) 27 0124 - Email: vnguemaandeme@yahoo.es Liberia 22. Mrs. Helena KAMARA, Program Manager, National Eye Care Program, Ministry of Health & Social Welfare, Capitol By-pass, P.O. Box l0-9009, 1000 Monrovia 10, Liberia - Tel: (+231) - Email: hkama_wvl@yahooo.com 23. Mr Abraham W. NYENSWAH, Deputy Program Manager, Ministry of Health & Social Welfare, Capitol By-pass, P.O. Box 10-9009, 1000 Monrovia 10, Liberia - Tel: (+231)6747602; (+231) 1 7 02521 5 - Email: nynswh@yahoo.com Malawi 24. Mr. Laston SITIMA, National Coordinator, CHSU, PlBag 65, Lilongwe, Malawi - Tel: +265 | 750 896; + 265 888 303 446 - Fax: +265 1753 308 - Email: laston-sitima2000@),ahoo.corn 25. Dr Lillian Matolase GONDWE CHLTNDA, District Health Officer, Blantyre District Health Office Private Bag 66 Chichiri, Blantyre 3, Malawi - Tel: (+265) 995249724 - Fax (+265) | 872551 - Email : lmchunda(Ogmai l.corn Nigeria 26. Dr Michael ANIBUEZE, Director, Public Health, Federal Ministry of Health, New Federal Secretariat Complex, Shehu Shagari Way, P.O. Box 083, Garki, Maitama-Abuja, Nigeria - Tel: (+234) 8033 |39 41 4 - EmaiI: rnikiariibueze@I ive.cem 27 Dr Emmanuel C. MERIBOLE, Technical Assistant to the Honourable Minister of Health, New Federal Secretariat Complex, Shehu Shagari Way, P.O. Box 083, Garki, Maitama-Abuja, Nigeria - Tel: (+234) 8023071624 - Email: meribole@yahoo.corn 28 Mr. Chukwu OKORONKWO, Programme Officer, National Onchocerciasis Control Programme (NOCP), New Federal Secretariat Complex, Shehu Shagari Way, P.O. Box 083, Garki, Maitama- Abuja, Nigeria - Tel: (+234) 80336198945 - Email: chukoro christ@yahoo.co.uk 29. Mr. Sulaiman AUDU, Protocol Officer, New Federal Secretariat Complex, Shehu Shagari Way, P.O. Box 083, Garki, Maitama-Abuja, Nigeria Tel: (+234) 8036050451 - Email: kamishe2000@yahoo.corn Sudan/Soudan 30. Dr Tabita SHOKAI, Honourable Federal Minister of Health, Ministry of Health, Khartoum, Sudan - Tel: (+249) 183774381; (+249) 9 12309 169 - Email : fmohshokai@vahoo,com JAFI6.4 Page22 3 l. Dr Hashim Mohamed Osman KAMAL, Chairman of the NOTF, Director, Prevention of Blindness Administration, Federal Ministry of Health, Nile Avenue, P.O. Box 630, Khartoum, Sudan - Tel:(+249) 183741422 Fax: (+249) 183741421 Mobile: (249) 912309628 Email: kamalbinawi@yahoo. com 32. Dr. Adil SULIEMAN MOHAMED, Federal Khartoum, Sudan - Tel: (+249) 912332880 - Southern Sudan/Sud Soudan Ministry of Health, Curative Medicine Department, Email rowah ail.com 33. Dr Nathan RIAK ATEM, Director General for Preventive Medicine, Ministry of Health, Government of Southern Sudan, Juba - Tel: (+249) 907710546 - Email: aternda@grnail.corn 34. Dr Mounir LUGGA, Director NTDs, Ministry of Health, Government of Southern Sudan, P.O. Box 88, Juba, South Sudan Tel: (+249) 122254313; (+249) 926590019 Email: mounir_lado@yahoo.co. uk 35. Mr F. BIZIINEH, NGDO Coordinator, CBM-Kenya, South Sudan - Tel: +254-125954971 - Fax: +254-02037 5 1654 - Email: fbchane@yahoo.com Tanzania/Tanzanie 36. Prof David H. MWAKYUSA (MP), Honourable Minister of Health and Social Welfare, Samora Avenue, P.O. Box 9083, Samora Avenue, Dar-es-Salaam, Tanzania - Tel: +255 22 2127192 - Fax: +255 22 2138060 - Email: dmwak),usa@rnoh.go.tz 37. Dr Donan William MMBANDO, Director for Preventive Services, Medical Doctor, Public Health Physician, Ministry of Health and Social Welfare, P.O. Box 9083, Samora Avenue, Dar-es- Salaam, Tanzania Tel: 255 22 2120061-7 Fax: +255 22 2138060 Email: dwmmbando@hotmai1.com 38. Dr Nkundwe G. MWAKYUSA, Program Coordinator, Ministry of Health and Social Welfare, P.O. Box 9083, Samora Avenue, Dar-es-Salaam, Tanzania - Tel: +255 22 2130025 - Fax: +255 22 2 I 30009 - Email: tukku29@.yahoo.com 39. Mr. Titus Aloyce MKAPA, Minister's Private Secretary, Ministry of Health & Social Welfare, Samora Avenue, P.O. Box 9083, Samora Avenue, Dar-es-Salaam, Tanzania - Tel: +255 22 2127192 - Fax: +255 22 2138060 - Email: tamkapa@yahoo.com Uganda/Oueanda 40. Dr Stephen Oscar MALIINGA, Honourable Minister of Health, Ministry of Health, P.O.Box7272, Kampala, Uganda - Tel: (+256) 772404703 - Email: smallingal@yahoo.corn 41. Dr Dennis Wilfred Kigambe LWAMAFA, Commissioner Health Services, Department of National Disease Control, Ministry of Health, P.O. Box 7272 Plot 6, Lourdel Road, Nakasero, Kampala, Uganda - Tel./Fax: (+256)414-259-666 - Fax: (+256)414-348-339 - Email: lwamafa@yahoo.co.uk; lwamafa@hotmail.com 42. Mr. Tom Luroni LAKWO, Senior Entomologist, National Onchocerciasis Control Programme (NOCP) Secretariat, Ministry of Health, 15 Bombo Road, P.O. Box 1661, Kampala, Uganda- Tel: (256) 414 348-332; Mobile: (+256) 772-438-311 - Fax: (+256) 414-348-339 - Email: lakwo200l @yahoo.corn 43 44 JAFI6.4 Page23 OCP COI]NTRIES/PAYS OCP Burkina Faso Dr Sylvestre Roger Marie TIENDREBEOGO, Directeur de la Lutte contre la Maladie, 03 B.P. 7009, Ouagadougou 03, Rdpublique du Burkina Faso - Tel: (+226) 70 25 94 38 - Fax: (+226) 50 3l 54 40 - Email: syltiend@hotmail.com Cdte d'Ivoire Dr R6mi ALLAH KOUADIO, Ministre de la Santd et de l'Hygidne Publique, Ministdre de la Santd et de l'Hygidne Publique B.P V4, Abidjan, R6publique de Cdte d'Ivoire -Tel: (225) 20 21 08 7l - Fax: (+225) 20 22 22 01 - Email: allahremi@)zahoo.fr 45 Dr Marie Madeleine KOUAKOU IILLINGA, Directeur Coordonnateur du PNLC6, 25 8.P.299, Abidjan 25, Cocody-Danga, R6publique de C6te d'lvoire - Tel: (+225) 22 44 31 0l - Cellulaire:(+225) 07 08 38 03 Fax: (+225) 22 44 31 83; (+225) 22 44 31 0l Email: magdy koua(@yahoo.fr Dr Pierre Gbayoro BzuKA, Directeur Coordonnateur Adjoint du PNLC6, Ministdre de la Sant6 et de l'Hygidne Publique,06 BP 7172 Abidjan 06, R6publique de C6te d'Ivoire -Tel: (+225)09 24 27 77 - Fax: (+225) 22 44 37 01 - Email: gbayoropierre@.vahoo.fr Ghana 47 Dr Joseph Akkesi AMANKWAH, Director, Public Health Division, Ministry of Health, P.O. Box M44, Ministries, Accra, Ghana - Tel: (+231) 21 68 08 92 -Email: joseph.amakwa@dhsmail.orgjaamankwa@)zahoo.corn Guinea/Guin6e 48. Dr Andr6 GOEPOGUI, Coordonnateur National, Programme National de Lutte contre I'Onchocercose et la Cdcit6 (PNLOC), Ministdre de la Santd et de l'Hygidne Publique, BP 585, Conakry, R6publique de Guinde -Tel: (+224) 60 29 3l 59 - Email: agoep@yahoo.fr Guinea-Bissau /Guin6e Bissau 49, Dr Augusto Paulo DA SILVA, Secr6taire d'Etat de la Santd, Ministdre de la Santd Publique, Av. Clinidade C.P. l0l3 - 50, Guin6e Bissau - Tel: (+245) 672 99 78 - Mobile: (+245) 663 30 27 - Email: augustopau lo. si Iva@smai l.corn 50 Dr Ramalho Joao CORREIA, Directeur R6gional de la Sant6 et Coordonnateur National Oncho, Ministdre de la Sant6, B.P.50, Gabu, Guinde Bissau, Tel: (+245) 677 19 16 - Email: rantoni a2006@yahoo.es Mali 51. Dr Mamadou Oumar TRAORE, Coordonnateur du Programme National de Lutte contre l'Onchocercose, Direction Nationale de la Sant6, B.P. 233, Bamako, Rdpublique du Mali - Tel: (+223) 66 7 I 17 66; (+223) 20226497 - Email : traorernot@yahoo.fr 46. JAFI6.4 Page24 Niger 52. Dr Mallam Ekoye SAIDOU, Secr6taire G6n6ral, Ministdre de la Sant6 Publique, BP 623 Niamey, R6publique du Niger, Tel: (fl)1196021617 - Email: ekoye_saidou@yahoo.fr Dr Adamou SALISSOU, Coordonnateur National, Programme National de D6volution Onchocercose et Elimination de la Filariose Lymphatique (PNDOFL), BP 623, Niamey, R6publique du Niger - Cellulaire: (+227) 96 96 03 76 - Fax: (+227) 20 35 03 46- Email: sadamouba@yahoo.fr 53 Sierra Leone 54. Dr Santigie SESAY, Programme Manager, ONCHOA,ITDs Control Programmes, c/o New England Ville, Freetown, Sierra Leone -Tel: (+232) 76 60 4658 - Email: sann qmail.com Togo 55. Dr Kof[ Potochoziou KARABOU, Coordonnateur, Programme National de Lutte contre l'Onchocercose, BP 487 DRS/Kara, R6publique Du Togo - (+228) 660 17l0; (+228) 660 00 35 - Cellulaire: (+228) 902 47 95 - Fax: (+228) 660 04 14 - Email: karaboup@),ahoo.fi. DONORSIDONATEURS African Development Bank/Banque Africaine de Ddveloppement 56. Mr. Thomas HURLEY, Directeur, Ddpartement du Ddveloppement Humain (OSHD), Banque AfricainedeDdveloppement(BAD), l3RueduGhana, l002,Tunisie-Tel: (+216)71 lO2046- Email : t.hurle),@afdb.org 51. Dr Tshinko Bongo ILUNGA, Chef de Division, Division Sant6, D6partement du Ddveloppement Humain (OSHD.3), Banque Africaine de D6veloppement, 13 Rue du Ghana, 1002, Tunis, Tunisie, Tel: (+216) 7l l0 21 17, Email: t.ilunga@afdb.org 58. Mr. Mohamed Mohsen CHAKROUN, MD, MPH, Expert en Sant6, (OSHD.3), Banque Africaine de D6veloppement, Avenue Hedi Nouira,B.P.323,l002 Tunis Belvdddre, Tunisie, Tel (+216) 7l l0 25 I l, - Email: rn.chakroun@afdb.org 59 Dr Maimouna DIOP LY, Analyste Supdrieure en Sant6, BAD, Division de la Sant6, OSHID.3, l3 Rue du Ghana, 1002, Tunis Belv6ddre, Tunisie - Tel: (+216) 7l l0 34 35 - Email: m.dioply@afdb.org 60 Mrs. May Ali BABIKER, Sp6cialiste en Genre, D6partement du D6veloppement humain (OSHD.O), Banque Africaine de D6veloppement (BAD), 13 Rue du Ghana, 1002, Tunis, Tunisie - Tel: (+216) 7l l0 33 66 - Email: m.babiker@afdb.org Dr Nadine YONGUI ABIOLA, Consultant, D6partement du D6veloppement humain (OSHD.3), Banque Africaine de D6veloppement (BAD), l3 Rue du Ghana, 1002, Tunis, Tunisie - Tel: (+216) 7l 10 26 17 - Email: n.yonguimassok@afdb.org Mrs. Shu Shu TEKLE HAIMANOT, Principal Health Analyst, D6partement du Ddveloppement humain (OSHD.O), Banque Africaine de D6veloppement (BAD), 13 Rue du Ghana, 1002, Tunis, Tunisie - Tel: (+216)259 15084 - Email: s.tekle-hairnanot@afdb.org 6t 62 63 64 66 JAFI6.4 Page 25 Mr. Walter MUCHENJE, Chief Health Analyst, Ddpartement du D6veloppement humain (OSHD.0), Banque Africaine de D6veloppement (BAD), 13 Rue du Ghana, 1002, Tunis, Tunisie - Tel: (+216) 7l1024 43 -Email: w.muchenge@afdb.org Mr. Mohamed Mahdi YOUSSOUF, Lead Health Analyst, D6partement du Ddveloppement humain (OSHD.0), Banque Africaine de D6veloppement (BAD), 13 Rue du Ghana, 1002 Tunis Belv6ddre, Tunisie - Tel: (+216) - Email: m.youssou f@afdb.ore 65 Mrs. Bineta BA DIAGNE, Chief Health Analyst, D6partement du Ddveloppement humain (OSHD.0), Banque Africaine de D6veloppement (BAD), Avenue Hedi Nouira, BP 323, 1002 Tunis Belv6ddre, Tunisie - Tel: (+216) 7I l0 23 06 - Email: baba-diagne@afdb.org Dr Olayide FATOYINBO, Consultant, 58, Rue du Parc, LA-Soukra, Tunis, Tunisia - Tel: (+216) 25 0 5 0662 - Emai I : o lay i defatoyinbo@-vahoo.co. uk Belgium/Belgique 67. Dr Ignace RONSE, Expert Sant6, Ministdre de la Coop6ration Internationale, KarmelietenStraat, 15, 1000 Brussels, Belg ium - Tel: 003225014379 - Email: lsnace.Ronse@diplobel.fed.be Canada 68. Ms Nathalie GARON, Agent Principal de D6veloppement, Agence Canadienne de Ddveloppement, 200, Promenade du Portage, Gatineau Qudbec, KIA 0G4, Canada - Tel: (+819) 9941088 -Fax: (+819) 997 5453- Email: nathalie.saron@acdi-cid a.sc.ca 69 Dr Pierre-Claver BIGIRIMANA, Thematic and Sector Specialists Division Geographic Programs Branch, CIDA, 200 Promenade du Portage, Gatineau (Qu6bec), Canada KIA 0G4 - Tel: (+819) - 953-2086 - Email: pierre_bigirimana@acdi-cida.gc.ca France '70 Dr Christian TOSI, M6decin Conseiller R6gional Secteur Sant6, Ambassade de France, Rue Alfassa, Brazzaville, Rdpublique du Congo Tel: +002426275761 Email: christian.tosi@d iplomatie. gouv.fr; christiantosi@.yahoo. fr Kitasato Institute 7t Professor Satoshi OMURA, Ph.D., President Emeritus, The Kitasato Institute, Professor Emeritus Kitasato University, 3-3-12 Okamoto Setagaya_ku, Tokyo, Japan - Tel: (+31) 03-7415-3744 Fax: (+81) 03 3415 3799 - Email: omuras@insti.kitasato-u.ac.ip 72 Prof. Andy CRUMP, Visiting Professor, Kitasato Institute/University, 2-7-ll shibaura Minato-Ku Tokyo 108-0023, Japan - Tel: (+81) 3 3456-0448 - Email: crumpa@,easynet.co.uk Kuwait Fund for Arab Economic Development Dr Abdul-Redha BAHMAN, Agricultural Advisor, Kuwait Fund for Arab Economic Development, P.O. Box 2921, Safat 13030, Kuwait - Tel: direct (+965) 22999186 Ext. (9186); (+965) 22 999 000 - Fax: (+965) 22 999 190 - Email: bahman@kuwait-fund.org Mr. Ayad I.Y.H. AL-GHARABALLI, Assistant Regional Manager, Kuwait Fund for Arab Economic Development, P.O. Box 2921, Safat 13030, Kuwait - Tel: (+!S5) ZZ 9g9ll5 - Fax: (+965) 22999 l90ll - Email: ayad@kuwait-fund.org IJ 74 JAFI6.4 Page 26 Merck and Co. Inc. 75. Mr. Kenneth M. GUSTAVSEN, Director, Access to Medicines, , Merck & Co., Inc., One Merck Drive WS2A-56, P.O. Box 100, Whitehouse Station NJ 08889-0100, USA - Tel: (+908) 423 3088 Fax: (+908) 735 1839 - Email: ken_gustavsen@merck.com Netherlands/ Pavs-Bas '16. Ms. Marja ESVELD, Senior Health Advisor, Social Development Department, Health and Aids Division, Ministry of Foreign Affairs, P.O. Box 20061 2500 EB, Den Haag, The Netherlands - Tel: * 31 70 3485304 - Fax: +31 70 3485366 - Email: rnarja.esveld@minbuza.nl Saudi Arabia/Arabie Saoudite 17. H. E. Eng. Hasan ALATTAS, Director General, Technical Department, The Saudi Fund for Development, P.O. Box 1887, Riyadh 11441, Kingdom of Saudi Arabia - Tel: +966-l-2194100 - Fax: +966-l -4647450 - Email: abamaan@),ahoo.corn 78. Mr. Saud ALFANTOUKH, Director General, Control & Audit Department, The Saudi Fund for Development, P.O. Box 1 887, Riyadh ll44l, Kingdom of Saudi Arabia - Tel: +966-l-4640723 - Fax: +966-l -4647450 - Email: safantoukh@glnail.com The World Bank/Banque Mondiale Dr C. OK PANNENBORG, Senior Health Advisor for Africa, Africa Region Human Development Department, The World Bank, 1818 H Street NW, Washington DC 20433, USA - Tel:202-473- 4415 - Fax: 202-413-8216 - E-mail: Opannenborg@worldbank.org Dr Donald A.P. BUNDY, Lead Specialist and APOC Coordinator, Africa Region Human Development Department, The World Bank, 1818 H Street NW, Washington DC 20433, USA - Tel:202-473-3636 - Fax: 202-473-8216 - Email: dbundy@worldbank.org Dr Andy TEMBON, African Region Human Development Department, The World Bank, l8l8 H Street, NW, Washington DC 20433, USA - Tel: 202- 458-4879 - Fax: 202-4738216, Email: atern bon@worldbank. org Mr. Alireza AZIMIPOUR, African Region Human Development Department, The World Bank, l8l8 H Street NW, Washington DC20433, USA - Tel: +202-458-2181 - Fax: +202-473-8216 - Email : aazimpour@worldbank.org United States of America/Etats Unis d'Amdrique 83. Ms. Angela WEAVER, Neglected Tropical Disease Advisor, U.S. Agency for International Development (USAID), GH/FIIDN/ID, Room 3.07-27, 1300 Pennsylvania Avenue, NW, Washington,DC,20523, USA - Tel: +l 202-712-5603 - Email: aweaver@usaid.gov 84. Dr Eric A. OTTESEN, Technical Director, RTI Intl. - NTD Control Program, 805 l5'h Street, N.W., Washington, DC 20005, USA - Tel: +l 404-275-0758 - Fax: +1 202-974-7892 - Email: eottesen@rti.org 79 80 81 82 JAFI6.4 Page27 NGDOs/ONGD Carter Center 85. Dr Frank O. RICHARDS, Jr., Director, Malaria, River Blindness, Lymphatic Filariasis & Schistosomiasis Programs, The Carter Center, One Copenhill Avenue, 453 Freedom Parkway, Atlanta, GA 30307, USA - Tel: 770-488-451 I - Fax: 770-488-4521 - Email: friqh0l@-emory.edu Ms Nichole KRUSE, Chief Development Officer, Health Programs, the Carter Center, 453 Freedom Parkway, Atlanta, GA 30307, USA - Tel: 404 420 5132 - Fax: 404 688 l70l - Email: nkruse@emory.edu CBM 87. Prof. Allen FOSTER, President, Christoffel-Blindenmission (CBM) e.V. Nibelungenstrasse 124, D-64625 Bensheim, Germany, Tel.(+49) 62 51 131- 300, Fax: (+49) 62 51 131-309, Email: al len.foster@cbrn.org; overseas@cbm.org Centre for Neslected Trooical Diseases - Liverpool School of Tropical Medicine 86. 89 88 Prof. Moses BOCKARIE, Director, Centre for Neglected Tropical Diseases (CNTD)/Liverpool School of Tropical Medicine (LSTM), Pembroke Place, Liverpool, L35QA, UK - Tel 44151 705 3343 - Email: rnib@liv.ac.uk DFID (Global Alliance for Elimination of Lymphatic Filariasis - GAELF) Prof. David H. MOLYNEUX, Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool, United Kingdorn - Tel: + 44-15l-705-3291; +44-7780-991-824 - Email : davrd.molyneux@l ivevrpool.ac.uk Helen Keller International (HKI) 90. Mr Chad MACARTHUR, Director of NTD Control, Helen Keller International (HKD, 532 Park Avenue South, 12th floor, New York City, NY 10010, USA - Tel. +1-212-532-0544 - Fax: +1- 212-532-6014 - Email: cmacarthur@hki.ore Institut de Recherche le Ddveloppement (lRD) 9t Dr Michel BOUSSINESQ, lnstitut de Recherche pour le Ddveloppement (IRD), UMR-145,911 avenue Agropolis, BP 64501, 34394 Montpellier Cedex 5, France, Tel: +33 4 67416162 - Fax: +33 4 67 41 63 30 -Email: boussinesq@ird.fr Lions Clubs International Fondation (LCIF) 92. Mr. Karim BENGRAINE, Program Coordinator, 300 W. 22"d Street, Oak Brook, IL 60523, USA - Tel: +l-630-468-6825 - Fax: +l-630-706-917 8 - Email: karim.bensrai ne(@lionsclubs.ors Mectizan@ Donation Program 93 Dr Adrian HOPKINS, Director, Mectizan Donation Program, 325 Swanton Way, Decatur, GA- 30030, USA - Tel +l 404-371-1460 - Fax: +l 404-371-l138 - Email: ahopkins@taskforce.org Dr Kisito OGOUSSAN, Associate Director (Onchocerciasis), Mectizan Donation Program, 325 Swanton Way, Decatur, GA- 30030, USA - Tel +l 404-687-5633 - Fax: +l 404-371-1138 - Email : kogussan@taskforce.ors 94. JAFI6.4 Page28 MITOSATH 95. Mrs. Francisca O. OLAMIru, Executive Director, Mission to Save the Helpless (MITOSATH), 605 Hospital Place, Opposite Green Valley Suites, GRA, P.O. Box 205, Jos - Plateau State, Nigeria, Tel: (234) 73 464 792 - Mobile (T\ 8033318085 - Email: mitosath@hotmail.com or olam ij ufo@m itosath.org Organisation pour la Pr6vention de la Cdcitd (OPC) 75. Dr Bernard PHILIPPON, Charg6 de Mission, Organisation pour la Pr6vention de la C6cit6 (OPC), l7 Villa d'Alesia, 75014 Paris, France - Tel: (0033) 0l 44 12 41 90; Fax: (0033) 0l 44 12 23 0l - Email: abphilippon@yahoo.fr; opc@opc.asso.fi' Sight Savers lnternational (SSI) 76. Mr. Simon BUSH, Director of African Alliances and Advocacy, Sight Savers lnternational (SSI), P.O. Box KIA 18190 Airport, Accra, Ghana- Tel: +233 21 774210 - Fax: +233 21 114209 - Email : sbush@si ghtsavers.org wHo/HQ/GENEVA-OMS/SIEGE/GENEVE 17. Dr Denis DAUMEzuE, World Health Organization (WHO) , 20 Avenue Appia, 72ll Geneva 27, Switzerland - (Direct) Tel: +41-22-791-2111 - Email: daumeried@who.int 78 Mr Claude-Henri VIGNES, Legal Adviser, Office of the Legal Counsel, c/o World Health Organization (WHO), 20 Avenue Appia, CH-1211, Geneva 27, Switzerland Email: chYlelcr@bberryln qh Mr Gian Luca BURCI, Legal Counsel, Office of the Legal Counsel, World Health Organization (WHO),20,AvenueAppia,CH-l2ll,Geneva2J,Switzerland,Tel: -41-22191-4754,Fax:+41-22 7 9 I -4846, Email: burcig@who.int 80 Mr. Xavier DANEY, Legal Officer, Office of the Legal Counsel, World Health Organization (WHO), 20 Avenue Appia, CH-1211, Geneva 27, Switzerland - Tel: +41-22791-1811- Fax: +41 -22 1 9 I -4846 - Email: danelx@who.int 8l Dr Badara SAMB, Adviser to the Assistant Director-General, Health System and Services Cluster (HSS), World Health Organization (WHO), 20 Avenue Appia, CH-121l, Geneva 27, Switzerland Tel: 4l 22 781 4452 -Fax: 4l-22 791-4817 - Email: sambb@.who.int Dr Annette Christiane KUESEL, Scientist, TDR, World Health Organization, 20 Avenue Appia, l2ll Geneva 27, Switzerland, Tel: +41-22791-1541 - Fax: +41-22791-4774 Email: kuesela@who.int Dr Tony UKETY , NGDO Group Responsible Officer, World Health Organization (WHO), 20 Avenue Appia, l2l I Geneva 27 , Switzerland - Tel: +41-22-791-1450 - Fax: +41-22-791-4772 - Email: uketlt@who.int WHO/AFRO/OMS AFRO Dr Luis Gomes SAMBO, Regional Director, World Health Organization Regional Office for Africa (WHO/AFRO), Cit6 du Djou6, BP 06, Brazzaville, Congo - Tel: +47 24139 351 - Email: sambol@afro.who.int 79 82 83 84 85 86. 81 JAF16.4 Page29 Dr Chris MWIKISA, Director, Division in Health System Development, World Health Organization Regional Office for Africa (WHO/AFRO), Citd du Djou6, BP 06, Brazzaville, Congo -Tel: +47 24 139 388 - Email: mwikisac@afro..who.int WHO/IVID S C - OM S/IVID SC Prof. Evariste MUTABARUKA, Director a.i., Multi Diseases Surveillance Center (MDSC), Avenue Naba Zombr6 N' 1473, 01 B.P. 549, Ouagadougou 01, Burkina Faso - Tel: (+226) 70 20 02 63 - Fax: (+226) 50 34 28 75 - Email : mutabarukae@oncho.afro.who.int WHO/SECRETARIAT-SECRETARIAT OMS 88 Dr Uche Veronica AMAZIGO, Director, APOC, Avenue Naba Zombr6 No 1473, 0l P.O. Box 549, Ouagadougou 01, Burkina Faso - Tel: (+226) 50 34 22 77 - Fax: +(226) 50 34 48 00 - Email: amazi gouv@oncho.afro.who. int Dr Laurent YAMEOGO, Coordinator, Director's Office, APOC, Avenue Naba Zombre No 1473, 0l P.O. Box 549, Ouagadougou 01, Burkina Faso - Tel: (+226) 50 34 41 04 - Fax: (+226) 50 34 28 1 5 - Email: yameogol@.oncho.afro.who.int Dr Mounkaila NOMA, Chiei Epidemiology and Vector Elimination Unit, APOC, Avenue Naba Zombre No 1473,01 P.O. Box 549, Ouagadougou 01, Burkina Faso -Tel: (+226) 50 34 29 53 - Fax: (+226) 50 34 28 75 - Email: nomam@oncho.afro.who.int Mr Honorat Gustave ZOURE, Responsible, Biostatistics and Mapping, APOC, Avenue Naba Zombre No 1473,01 P.O. Box. 549, Ouagadougou 01, Burkina Faso -Tel: (+226) 50 34 29 59 - Fax: (+226) 50 34 28 75 - Email: zoureh@oncho.afro.who.int Dr Grace Fobi, COP/APOC, Avenue Naba Zombr6 N' 1473, 0l P.O. Box 549, Ouagadougou, Burkina Faso, Tel: (+226) 50 34 29 53, Fax: (+226) 50 34 28 75,Email: fobig@oncho.afro.who.int 92. Mr. Koffi Benoit AGBLEWONU, Budget and Finance Officer, APOC, Avenue Naba Zombre No 1473,01 P.O. Box 549, Ouagadougou 01, Burkina Faso - Tel: (+226) 50 34 29 53 - Fax: (226) 50 34 28 75 - Email: agblewonuk@oncho.afro.who.int Mrs. Patricia MENSAH, Senior Administrative Assistant, Sustainable Drug Distribution Unit, APOC, 0l P.O. Box 549, Ouagadougou 01, Burkina Faso - Tel: (+226) 50 34 29 53 -Fax: (+226) 50 34 28 75 - Email: rnensahp@oncho.afro.who.int Mrs. Ida SAVADOGO, Secretary, APOC, Avenue Naba Zombrd N" 1473,01 P.O. Box 549, Ouagadougou 01, Burkina Faso - Tel: (+226) 50 34 29 60 - Fax: (+226) 50 34 28 75 - Email: vu sbarel i@oncho.afro.who. inl! APOC TECHNICAL CONSULTATIVE COMMITTEE Prof. Adenike ABIOSE, P.O. Box 29771, Secretariat Main Office, Ibadan, Oyo State, Nigeria - T el: 23 4 -8037 8 6 57 02 - Emai I : abiose@skann et. com 89 90 9l 93 94 95 96 97 98 99 JAFI6.4 Page 30 INTERPRETERS/INTERPRETE S Mr. Christian STENERSEN, 123 Les Rossanets, F-01170 Segny (France)-Tel: +33 450417880 - Email: christian.stenersen@oran ge.fr Ms Genevidve CLEMENT, Le Parc du Jura, 42 avenue du Jura, F-01210 Ferney-Voltaire, France - Tel: +33 456820578 - Email: g.clement@club-internet.fr Mme Safi6tou BARRY, 09 B.P. 526 Ouagadougou 09, Burkina Faso - Tel: (+226) 50 46 02 82, cellulaire (+226) 10 21 4l 14; (+226) 78 03 64 55 - Email: barrysafietou@email.com Mr. Victor IMBOUA-NIAVA, 3 Maple Crescent, DTD, Silver Bells 2, Regimanuel Estates, East 21811934 - Email: vimbouaniav .com 100. Mme Anthea BLACKHURST GOMES DA SILVA, Conf6rence/lnterprdte, Rua Vasco da Gama, 27, Alto do Lagoal, 2760-119 Caxias, Portugal - Tel: +351 21442 63 00 - Email: artheabl ag khurst@,m ai l. te lepac. pt 101. Mrs. Montserrat CASANOVA, Conference Interpreter, Calle Itaca 44 ES-2822 Majadahonda, Madrid, Spain - Landline: +34-610 46 3l 7 5 - Email: montserrat.casanova@.yahoo.com 102. Mrs. Ruth CARRERAS, Conference Interpreter, Cami del Colomer,3-9,28 08172 Sant Cugat del Valles, Barcelona, Spain - Mobile: +34 93 589 6397 - E-mail: rcarrerab@yahoo.com 103. Mrs. Sofia VARELA HALL, Conference Interpreter and Translator, Chef-Lieu,74270 Contamine- Sarzin, France - Tel : +3363779987 - Email: sofiavarelahall@hotmail.com 104. Ms. Pamela Del Pilar VALDES RIVERA, Freelance Conference Interpreter, Rue Etienne-Dumont 3,7204, Gendve, Suisse -Tel: +41797825207 - Email: world_interpreting@yahoo.com 105. Mr. Mourad BOULARES, Interprdte Confdrencier, free-lance, I bis rue d'Am6rique, La Marsa, Tunisie - Tel: (+2 l6) 2l l0 49 47; +0033 608003270 - Email: mouradboulares@hotmail.com 106. Professeur Michel KABORE (Traducteur) 0l B.P. 1444, Ouagadougou 01, Burkina Faso, Tel: (226) 50 36 13 83 - Cellulaire: (226)7027 05 96, Email: kaborein@cenatrin.bf RAPPORTEURS 107. Dr Stephen LEAK, Technical Officer, Avenue Naba Zombr6 No 1473, 0l Box 549, Ouagadougou, Burkina Faso, Tel: (+226) 50 34 29 53, Fax: (226) 50 34 28 75, Email: leaks@oncho.afro.int 108. Elizabeth NYAMAYARO, Health, Nutrition and Population, The World Bank, 1818 H StreetNW, MS G7-701, WashingtonDC 20433, USA, Tel +l-202-473-5473 Fax +1-202-522-3489, Email: enyamayaro@worldbank.org 109. Ms Juliet OCHIENGHS, Administrative Officer, World Health Organization (WHO), 20 Avenue Appia, l2ll Geneva2T,Switzerland - Tel:+41-22-791-12580 -Fax: +41-22-791-4772 - Email: ochienghsj@who.int Airport, Accra - Tel: (+233) a ait JAF16.4 Page 3 I INVITED PARTNERS/PARTENAIRES IIYVITES for Health Research I10. Dr Erling M. PEDERSEN, Senior Scientist, DBL - Centre for Health Research and Development, Faculty of Life Sciences, University of Copenhagen, Thorvaldsensve 57, l87l Frederiksberg C, Denmark - Tel: +45 35 33 14 06 - Fax: +45 35 33 14 33 - Email: emp@life.ku.dk ECCAS/CEEAC lll Dr Gabriel MALONGA MOUELET, Mddecin, Communaut6 Economique des Etats de l'Afrique Centrale (CEEAC/ECCAS), B.P. 2112, Libreville, R6publique Gabonaise - Tel +241-07- 65.32.39;+241-06-23-78-99 -Fax: +241-44-47-32-Email: sabriehnalonga@yahoo.fr Pfizer tt2. Mr. Pol VANDENBROUCKE, Vice president, Development - Emerging Markets,Pftzer,235 East 42'd Street, New York, NY 10017, USA - Tel: +212-733-1114 - Fax: +641-441-6527 - Email: po l. vandenbroucke@pfi zer.com 113. Mr. Nand KUMAR, Director, Access Programs for Developing Countries, Pfizer,500 Arcola Road Collegeville PA 19426, U.S.A - Tel: +484-865-3351 - Fax: +484-865-6419 - Email: kurna13 8@pfizer.corn ll4. Mr. Ken SCHANBACHER, Associate Director, Project Management, Pfrzer,500 Arcola Road, Collegeville, 19426, USA Tel: +484-865-2364 Fax: +484-865-9197 Email: schanb(@pfi zer.com ant6 ll5. Dr Placido Monteiro CARDOSO, Directeur G6n6ral, Organisation Ouest Africaine de la Sant6 (OOAS), 0l BP 153, Bobo-Dioulasso, Burkina Faso, Tel: (+226) 20 97 57 75 - Fax: (+226) 20 97 5 7 7 2 - E m a i | : wah ooas @fasonet. bf; placar2} 02 @,h otm ail.fr 116. Dr Doulaye SACKO, Professionnel en charge du Programme Vision 2020, Organisation Ouest Africaine de la Sant6 (OOAS), 01 BP 153, Bobo-Dioulasso, Burkina Faso, Tel: (+226) 20 97 57 7 5 Fax: 226 20 97 57 72 - Email: wahooas@fasonet.bf: wahooas@wahooas.org; baye sacko2 0 0 0 @yahoo. fr 117. Mr Salifou ZOUMA, Directeur de la Planification et de l'Assistance Technique, Organisation Ouest Africaine de la Sant6 (OOAS), 0l BP 153, Bobo-Dioulasso, Burkina Faso, Tel: (226) 20 97 57 75 - Fax: (+226) 20 97 57 72 - Email: wahooas@fasonet.bf; wahooas@wahooas.org; szouma@wahooas.org; yzsal ifou@yahoo.fr II{VITED SPEAKERS/ORATEURS II\"WTES ll8. Prof. Dik HABBEMA, Professor of Medical Decision Sciences, Department of Public Health, Erasmus MC, University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands - Tel: +31 l0 7030049 - Email: j.d.f.habbema@erasmusmc.nl l19. Dr Hans F. REMME, 120 rue des Campanules 0120 Ornex, France -Tel: +33 64545 74 04 - Email: hansremme@gmail.com t JAFI6.4 Page 32 NI-VITED GUE ST/ II{\{ITE 120. Mrs. AMITY Meria, Directrice Casais Production, 09 BP 555, Ouagadougou 09, Burkina Faso - Tel: (00226) 50 45 77 53 121 Mrs. Upendo Amon KILAHIRO, Singer, P.O. Box 759, Dar-es-Salaam, United Republic of Tanzania - Tel: +255-7575781l4 - Email: upendokilahiro@hotmail.com APOC Management 10.12.2009 a ? , JAF16.4 Page 33 Annex 2 African Programme for Onchocerciasis Control (APOC) Programme africain de lutte contre I'onchocercose JOINT ACTION FORUM JAF-FAC FORUM D'ACTION COMMUNE Office of the Chairman Bureau du Pr6sident JOINT ACTION FORUM JAF15.2 Fifteenth session Tunis (Tunisia). 8-10 December 2009 Revision 1 PROVISIONAL AGENDA Opening 1. Opening of the session Tribute to the late Mr R. McNamara Election of Officers Adoption of Agenda Reflections of the Comrnittee of Sponsoring Agencies 2 ) 4 5 CDTI: 6. 7. 8. 9. 10. 11. Im plem entatio n/lVIon ito ring/Evaluation/Su rveillance Report of the World Health Organization Country reports: treatment coverage, Governments and NGDOs' financial contributions Report of the Technical Consultative Committee (TCC) Sub-regional meetings on cross-border collaboration: Special report by the Governments of Burkina Faso and Cameroon Status of Onchocerciasis Control in fonner OCP countries Elimination of Onchocerciasis transmission in Africa: recent evaluation studies and implications for shrinking the map t ! Strengthening health systems and Co-implementation 12. Co-implementation: Special report by the Governments of Tanzania and Democratic Republic ofCongo 13. Capacity building of countries Closed session 14. Closed session of Ministers of Health, donors and NGDOs Research and Drug Development 15. Health Impact Assessment of APOC operations 16. Current research within APOC and TDR Collaboration Partnership 11. Report of the NGDO Coordination Group for Onchocerciasis Control 18. Multi-Disease Surveillance Centre (MDSC) Programme management and Finance 19. Audit report 20. Addendum to the PIan of Action and Budget 2008-2015 21. PIan of Action and Budget for 2010-201 I 22. Financing of the African Programme for Onchocerciasis Control (APOC) 23. Pledging of Donor contributions Final Communiqu6 and closure 24. Date and place of the sixteenth session 25. Final Communiqu6 26. Closure of the fifteenth session DIR/APOC/31.10.2009 I ?s , I 7